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ABSTRACT	
Glioblastoma	multiforme	(GBM)	is	the	most	aggressive	and	prevalent	type	of	primary	malignant	
brain	tumour	of	the	central	nervous	system,	predominantly	affecting	adults.	The	current	
medical	treatment	for	GBM	is	surgical	resection	combined	with	ionizing	radiation	(IR)	and/or		
chemotherapeutic	with	temozolomide.		However,	this	treatment	is	proved	to	be	insufficient	as	
it	only	provides	GBM	patients	with	a	one	year	survival	period	post-diagnosis.		GBM	cells	have	
been	found	to	develop	resistance	to	temozolomide	treatment.		Therefore,	the	discovery	of	
novel	therapeutic	agents	that	possess	the	capability	to	pass	through	the	blood	brain	barrier	is	
warranted	in	the	effective	management	of	GBM.		
Sterol	regulatory	element-binding	protein	1	(SREBP-1)	is	a	key	transcription	factor	involved	in	the	
regulation	of	 lipogenesis	through	regulating	gene	expression	of	proteins	 involved	 in	fatty	acid	
biosynthesis.	In	GBM	and	many	other	cancer	types,	overexpression	of	SREBP-1	has	been	found	
to	be	associated	with	 its	aggressive	pathological	 features.	Therefore,	SREBPs	can	be	potential	
targets	 for	 therapeutic	 treatment	 in	 GBM.	 	 We	 hypothesize	 that	 Indip	 and	 other	 SREBP1	
inhibitors	such	as	PF429242	and	fatostatin	arrest	the	proliferation	of	cells	in	a	well-established	
model	of	GBM	cells,	the	T98G	cell	line,	maintained	in	vitro	in	culture.		
The	present	study	 investigates	the	efficacy	of	SREBP-1	 inhibitors	such	as	 fatostatin,	PF429242	
and	a	recently	designed	short	cell	penetrating	bioactive	TAT-fused	peptide,	 indip,	 in	 inhibiting	
the	activation	of	SREBP-1	protein	as	well	as	proliferation	of	T98G	cells.	All	 three	compounds,	
fatostatin,	PF	429242	and	indip	led	to	significant	reduction	in	T98G	cell	growth	in	a	concentration	
and	time-dependent	manner.	Our	data	confirmed	that	this	effect	is	due	to	inhibition	of	SREBP-1	
iii		
activation	that	led	to	T98G	cell	line	apoptosis	resulting	in	reduction	in	cell	size,	cell	migration	and	
tumor	sphere	growth.	The	apoptotic	death	induced	in	T98G	cells	was	supported	by	a	more	than	
two	fold	increase	in	caspase-3	activity.		The	three	drugs	employed	arrested	the	proliferation	of	
T98G	cell	line	in	the	G2/M	phase	of	the	cell	cycle.	The	inhibition	of	SREBP-1	resulted	in	significant	
suppression	of	expression	of	key	downstream	lipogenesis	enzymes,	Stearoyl-CoA desaturase-1,	
fatty	acid	synthase	and	3-hydroxy-3-methyl-glutaryl-coenzyme A reductase		in	both	GBM		(T98G)	and	
human pancreatic carcinoma (MIA PaCa-2) cells.	 Furthermore,	 the	 combination	 of	 Indip	
(indirect)	and	PF429242	(direct)	treatment	had	the	greatest	effect	on	promoting	apoptosis	(87%	
cell	death),	compared	to	single	drug	treatment	(40	%	by	Indip	alone	and	60%	by	PF429242).	These	
data	 suggest	 that	 combination	 treatment	with	 SREBP-1	 inhibitor(s)	 along	with	 temozolomide	
could	be	considered	as	a	novel	therapeutic	approach	in	the	effective	management	of	GBM.	
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Chapter	1	
GENERAL	INTRODUCTION	 	
1.1	Lipid	metabolic	reprogramming		and	cancer	pathogenesis	
1.1.1	The	similarities	between	embryonic	and	cancer	cells	metabolism	
Over	fifty	years	ago,	it	was	noted	that	neoplastic	tissues	within	the	body	are	able	to	synthesize	
lipids	[1]	in	a	way	that	is	very	similar	to	the	function	of	embryonic	tissues.	Later,	in	1996,	
research	by	Kuhajda	found	that	a	prognostic	marker	in	breast	cancer	called	OA-519	
corresponds	to	fatty	acid	synthase	(FASN)[2].	Since	then,	more	research	has	determined	that	
tumor	cells	reactivate	de	novo	lipogenesis	as	well	[3].	Some	cancers,	including	breast	and	
prostate	[4–6],	have	demonstrated	increased	instances	of	FASN,	which	also	suggests	that	fatty-
acid	synthesis	plays	a	vital	role	in	metabolic	reprogramming		and	cancer	pathogenesisin	[3].	
1.1.2	The	main	characteristics	of	malignant	tumors	 	
Over	the	past	few	years,	the	field	of	cancer	metabolism	has	undergone	something	of	a	
resurrection	via	new	information	and	technologies.	Recent	studies	have	indicated	that	tumor	
cells	actually	reprogram	their	metabolic	networks—a	process	that	attempts	to	meet	the	
demand	for	extreme	growth	and	separation	that	is	typically	associated	with	these	cells	[13–15].	
The	main	characteristics	of	malignant	tumors	are	twofold:	first,	the	Warburg	Effect,	which	
exhibits	enhanced	glycolysis	while	a	tumor	maintains	normoxic	conditions,	and	second,	an	
increased	glutamine	metabolism	within	the	tumor	itself	[16–19].	Additionally,	exacerbated	
lipogenesis	is	also	a	recent	hallmark	of	cancerous	tumors	[20]—a	characteristic	that	research	
has	proven	correlates	positively	and	directly	with	enhanced	glucose	and	glutamine	metabolism	
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[21–23].	Considering	these	concepts	in	juxtaposition	with	each	other,	evidence	appears	to	
suggest	that	metabolism	reprogramming	could	be	a	major	player	in	determining	and	controlling	
malignant	tumor	growth	[17].	This	has	produced	a	promising	strategy	for	treating	cancer:	using	
targeted	altered	cellular	metabolism	during	de	novo	lipogenesis.	This	strategy	could	be	
effective	because	malignant	gliomas	contain	lipid	levels	in	the	tumor	tissue	that	are	higher	than	
normal	tissue,	indicating	a	correlation	that	could	respond	positively	to	this	method	[18].	
Accelerated	cholesterol	and	lipogenesis	are	hallmarks	of	cancer	and	are	key	elements	in	the	
process	of	malignant	transformation.	The	construction	of	new	cell	membranes	and	
maintenance	of	active	signaling	in	cancer	cells	relies	upon	this	high	intensity	of	de	novo	
lipogenesis	and	uptake	in	lipid	rafts.	
1.1.3		Insulin	resistance	and	Cancer	
Certain	alterations	in	the	metabolism	of	lipids	can	increase	predisposition	to	and	likelihood	of	
cancer	development	in	obese	patients.	In	terms	of	risk	association,	obesity	is	a	leading	factor	
associated	with	several	types	of	cancer	in	disease	risk	analysis,	with	current	estimates	
projecting	that	20%	of	all	cancers	and	50%	of	esophageal	and	endometrial	cancers	can	in	fact	
be	attributed	to	obesity	[19].	Obesity	contributes	to	high	cancer	risks	might	as	a	result	of	an	
acquired	insulin	resistance.	This	is	caused	by	the	gradual	buildup	of	lipids	in	liver	and	muscle	
cells,	which	leads	to	a	high	availability	of	intracellular	ceramide	and	diacylglycerol,	inhibiting	
insulin-stimulated	glucose	transport	and	impairing	insulin	signaling[20].	In	turn,	this	process	
leads	to	enhanced	secretion	of	insulin	from	pancreatic	b-cells,	increasing	the	level	of	insulin-like	
growth	factor	1	(IGF-1)	by	markedly	reducing	IGF-binding	proteins	1	and	2	[21].	Research	shows	
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that	both	insulin	and	IGF1	are	protumorigenic	growth	factors	that	can	stimulate	cancer	cell	
proliferation[22].	Increased	insulin	resistance	can	also	be	caused	by	chronic	inflammation	[23].	
Research	using	mouse	models	of	genetically-	or	diet-induced	obesity	have	revealed	that	the	
generation	of	hepatocellular	carcinoma	is	noticeably	reliant	on	the	production	of	inflammatory	
cytokines	as	well	[24].	
1.2	Lipogenesis	Pathway	
1.2.1		Epidermal	growth	factor	receptor	(EGFR)	regulates	SREBP-1	activation	
Several	Studies	have	shown	that	mutated	and	/	or	amplified	epidermal	growth	factor	receptor	
(EGFR)	have	been	shown	to	occur	in	50%	of	GBM	patients	[25].	Recent	study	has	shown	
oncogenic	EGFR	signaling	promotes	SREBP-1	activation	through	inhibiting	SCAP	by	enhancing	
miR-29	expression,	which	in	turn	upregulates	its	downstream	genes	to	support	rapid	GBM	
growth	[26].	In	addition	to	directly	activating	SREBP-1,	EGFR	signaling	in	human	glioblastoma	
multiforme	activates	SREBP1	in	a	mammalian	target	of	rapamycin	complex	1	(mTORC1)	
independent	manner	[27].	These	findings	demonstrate	that	EGFR	signaling	activates	SREBP-1	
through	elaborate	feedback	mechanisms.		
1.2.2		PI3K/Akt	signaling	and	SREBP-1	
PI3K/Akt	signaling	contributes	to	enhanced	glucose	uptake	and	glycolysis	[28]	by	regulating	
glucose	transporter	1	(GLUT1)	and	hexokinase	2	(HK2)	[17-18	].	Glucose	is	required	to	maintain	
high	ATP-levels	and	also	to	support	the	synthesis	of	NADPH	and	macromolecules,	such	as	lipids	
and	nucleic	and	amino	acids	[18].	PI3K/Akt	signaling	also	works	to	promote	fatty	acid	
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synthesis[30-31].	In	turn,	the	fatty	acid	synthesis	pathway	is	highly	regulated	by	SREBP-1,	which	
then	controls	the	expression	of	acetyl-CoA	carboxylase	(ACC)	and	FASN	[32].	FASN,	which	
mediates	the	final	step	of	the	synthesis	of	palmitate,	is	known	to	be	upregulated	via	PI3K/Akt	
signaling	[30-31].	Additive	glycolysis	is	a	key	identifying	trait	in	cancers,	even	when	these	
cancers	exist	in	oxygen-rich	conditions.	Cancer	cells	conglomerate	glucose	to	synthesize	fatty	
acids	in	order	to	promote	the	formation	of	new	cell	membranes	and	lipid	raft	[30].	Taken	
together,	PI3K/Akt	signaling	plays	an	important	role	in	activating	and	promoting	glycolysis	in	
which	SREBP-1	is	a	major	component	in	the	process	of	integrating	the	Glucose	carbon	flux	from	
PI3K/Akt	signaling,	as	regulated	by	aerobic	glycolysis	to	fatty	acid	synthesis.						
1.2.3	SREBP-1	integrates	glucose	and	glutamine	metabolic	influx	to	de	novo	lipogenesis	
The	metabolic	flux	from	glucose	and	glutamine	is	regulated	by	PI3K/Akt	signaling	and	C-Myc	
[33].	SREBP-1	has	been	proven	to	play	an	important	role		in	interconnecting	glutamine	
metabolism	and	oncogenic	signaling-regulated	glucose	metabolism	to	de	novo	lipogenesis	[34]	
First,	several	studies	have	shown	that		SREBP-1	activation	is	closely	regulated	by	PI3K/Akt	
signaling	pathway	in	cancer	cells,	in	addition	to	being	regulated	by	sterols	[35].	Two	possible	
mechanisms	exist	in	explanation	of	this	kind	of	regulation.	The	first	mechanism	implies	that	
active	Akt	can	enhance	stabilization	of		SREBP-1’s	nuclear	form	and	in	turn	enhance	its	target	
genes	expression	via	down-regulating	Fwb-7,	which	is	a	ubiquitin	enzyme	that	mediates	SREBP-
1’s	N-terminus	degradation	through	the	inhibition	of	its	regulator,	Glycogen	synthase	kinase-3	
beta	(GSK-3β)[36].	In	the	second	mechanism,	PI3K/Akt	signaling	pathway	can	regulate	SREBP-
1’s	transcriptional	activity	and	its	nuclear	localization	through	mammalian	target	of	rapamycin	
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complex	1	(mTORC1)	[37].	Ricoult	SJ’s	study	has	shown	that		oncogenic	mTORC1-SREBP	
signaling	plays	a	major	role	in	supporting	aberrant	proliferation	of	cancer	cells	by	inducing	de	
novo	lipogenesis	process	(38).		
It	has	recently	become	known	that	glutamine	also	contributes	to	lipid	synthesis	and	energy	
production	through	the	tricarboxylic	acid		(TCA)	cycle	[39-40].	Moreover,	the	oncogene	Myc	
promotes	glutamate	production	by	stimulating	the	glutamine	transporter	and	glutaminase.	The	
elevated	glutamate	in	turn	is	transported	into	the	mitochondria	for	α-ketoglutarate	synthesis.	
Afterwards,	α-ketoglutarate	can	then	contribute	to	ATP	synthesis	by	entering	the	TCA	cycle		
[39-40],	or	convert	into	citrate	via	reductive	carboxylation	under	defective	mitochondria	or	
hypoxia	conditions	to	promote	SREBP-1	driven	de	novo	lipogenesis	[33,	41].	Researchers	have	
recently	reported	that	glutamine	can	be	preferentially	chosen	by	cancer	cells	as	a	precursor	to	
the	synthesis	of	fatty	acid	during	an	impaired	mitochondria	condition	or	the	process	of	hypoxia	
[33,	41].	A	key	regulator	for	lipid	synthesis	through	glutamine	metabolism	could	potentially	be	
SREBP-1.		SREBP-1	plays	an	integral	role	in	connecting	oncogenic		Myc	regulated	glutamine	
metabolic	flux	and	PI3K/Akt	signaling-regulated	glucose	metabolic	flux	to	de	novo	lipogenesis	
[42].		Taken	together,	the	development	of	specific	inhibitors	made	to	target	SREBP-1	could	
create	a	new	therapeutic	strategy	in	treating	cancer,	particularly	in	cancers	with	oncogenic	Myc	
and	PI3K/Akt	signaling.	
1.3	Cholesterol		
1.3.1	The	mevalonate	pathway	
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Lipid	metabolism	also	features	another	vital	biosynthetic	process	called	the	mevalonate	
pathway,	which	induces	the	synthesis	of	cholesterol.	Cholesterol	biosynthesis	involves	the	
formation	of	3-hydroxy-3-methylglutaryl-CoA	lyase	(HMG-CoA	lyase)	by	combining	acetoacetyl-
CoA	and		acetyl-CoA.	HMG-CoA	is	reduced	to	mevalonate	by	3-hydroxy-3-methylglutaryl-CoA	
reductase	(HMGCoAR),	which	is	indicative	of	the	rate-limiting	reaction	of	the	cholesterol	
synthesis	pathway	and	is	meticulously	regulated.	The	stability	of	HMGCoAR,	an	endoplasmic	
reticulum-transmembrane	protein,	is	regulated	by	a	sterol-sensing-domain;	this	mediates	its	
degradation	under	saturating	sterol	levels	[43].	In	addition	to	forming	the	structural	backbone	
of	the	steroid	hormones,	cholesterol	is	a	crucial	component	of	cell	membranes;	it	controls	the	
fluidity	of	the	lipid	bilayer,	and	it	forms	lipid	rafts,	detergent-resistant	microdomains.[44].	
Furthermore,	cholesterol	biosynthesis	contributes	to	the	geranylgeranylation	of	Rho	and	the	
farnesylation	of	Ras,	which	are	both	required	for	the	isoprenylation	of	Guanosine	
triphosphatases	(GTPases)	[45].		
1.3.2		SREBPs	are	activated	in	response	to	low	sterol	conditions	
In	addition	to	being	able	to	escort	SREBPs	from	the	endoplasmic	reticulum	(ER)	to	the	Golgi	
apparatus,	sterol	regulatory	element-binding	protein	cleavage-activating	protein	(SCAP)	is	also	
considered	as	the	cholesterol	sensor.	When	sterol	levels	decrease,	SCAP	transports	SREBPs	
from	the	ER	to	the	Golgi	apparatus,	where	SREBPs	will	be	proteolytically	activated	and	help	
integrate	and	regulate	the	process	of	the	cholesterol	synthesis.		SREBP	in	turn	regulates	the	
expression	of	cholesterol		synthesis	enzymes	(46).		
1.3.3		HMGCoAR	is	the	target	for	statins	
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Cholesterol	buildup	has	been	demonstrated	in	prostate	cancer	(47),	while	alteration	of	the	
mevalonate	pathway	has	been	closely	linked	with	transformation	[48].	HMGCoAR	is	the	target	
for	statins,	which	are	a	class	of	cholesterol-lowering	drugs.	Several	cancer-cell	lines	
demonstrate	antiproliferative	activity	through	statins,	with	cell	cycle	arrest	in	breast	cancer	
cells	[49]	and	apoptosis	in	acute	myeloid	leukemia	[50].	Furthermore,	statin	treatment	has	
been	shown	to	enhance	the	sensitivity	of	chemotherapeutic	agents	toward	colorectal	cancer	
cells	by	inducing	epigenetic	reprogramming,	and	a	complex	combination	of	statins	with	
chemotherapy	has	demonstrated	encouraging	results	in	patients	afflicted	with	hepatocellular	
carcinoma	[51]	and	acute	myeloid	leukemia	[52].	Cancer	incidence	is	clearly	affected	by	statins,	
but	the	effects’	severity	and	usefulness	are	problematically	dependent	on	the	tumor	type	and	
the	class	of	the	statins	that	are	integrated	into	a	given	procedure.		
1.3.4		Cholesterol		esters	
								Several	researches	have	shown	that	cholesterol	esters	have	only	been	observed	in	high-
grade	gliomas	[53].	Cholesterol	esters	have	also	been	found	in	human	urothelial	carcinoma	and	
renal	cell	carcinomas	[54-55],	but	are	absent	in	the	corresponding	healthy	tissues	of	these	cells.	
By	compiling	this	information	together	contextually,	research	appears	to	demonstrate	that	
cholesterol	esters	can	be	a	future	biomarker	in	diagnosing	the	malignancy	of	specific	tumors	
[56].	Given	that	free	cholesterol	levels	are	strictly	controlled	through	negative	feedback	
mechanisms,	formation	and	accumulation	of	nascent	cholesterol	esters	could	be	the	method	
glioma	cells	use	to	store	cholesterol.	Cholesterol	esters	might	quickly	release	cholesterol	for	
both	growth	and	survival	mechanisms	in	cancer	cells,	particularly	when	cells	require	cholesterol	
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in	the	first	place.	Therefore,	as	cholesterol	esters	do	not	exist	in	healthy	brain	tissue,	stopping	
cholesterol	ester	formation	and	accumulation	may	be	a	promising	therapeutic	strategy	in	
attempting	to	inhibit	cancer	growth.	
1.4		SREBPs	
1.4.1	SREBPs	activation	pathway	
These	SBREPs	are	translated	as	125-kDa	precursors,	which	are	then	included	in	the	endoplasmic	
reticulum	membrane,	where	they	are	held	by	the	SREBP	cleavage-activating	protein	(SCAP).	
SREBP1a,	SREBP1c	and	SREBP2—three	SREBP	isoforms—have	been	recognized	in	the	cells	of	
mammals	[57].	SREBP1a	and	SREBP1c	are	created	through	alternative	splicing	and	differ	in	their	
expression	levels	across	various	types	of	cell	tissues;	SREBP1a	is	the	most	prominent	isoform	in	
cultured	cell	lines	[57].	Despite	there	being	an	overlap	in	their	target	gene	functionality,	SREBP1	
primarily	regulates	phospholipid,	fatty	acid	and	triacylglycerol	synthesis,	whereas	SREBP2	
monitors	and	dictates	the	expression	of	cholesterol-synthesis	genes	[57-58].	In	healthy	tissues,	
SREBPs	activation	is	closely	regulated	by	intracellular	sterol	levels	via	negative	feedback	
mechanism[59].		
The	N-terminal	domain	is	a	basic-helix-loop-helix	lucine	zipper	and	functions	as	the	
transcription	factor.	These	proteins	are	synthesized	as	ER	membrane	proteins	and	release	from	
the	ER	is	required	for	activation.	SREBP	is	found	as	a	complex	with	SCAP	and	insulin-induced	
gene	(Insig)	in	the	ER	[57].	Binding	of	Insig	to	SREBP-SCAP	blocks	translocation	of	the	SREBP-
SCAP	complex	to	the	golgi	apparatus,	where	SREBP	becomes	activated.	Sterol	deprivation	
promotes	the	dissociation	of	Insig	from	the	SREBP-SCAP	complex	promoting	movement	to	the	
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golgi	apparatus	[57].	In	the	golgi	SREBP-1	can	be	cleaved	by	site	1	and	site	2	proteases	[58].	
Thus,	the	N-terminal	of	SREBP-1	translocates	to	the	nucleus	and	binds	the	sterol	regulatory	
element	(SRE)	promoting	expression	of	lipogenic	genes	[58].	.	SREBP-1	has	been	found	to	
regulate	the	expression	of	a	number	of	proteins	involved	in	fatty	acid	synthesis	including;	
acetyl-CoA	carboxylase,	acetyl-CoA	synthetase,	acetyl-CoA	binding	protein,	ATP	citrate	lyase,	
fatty	acid	synthase,	peroxisome	proliferator-activated	receptor-g,	malate	dehydrogenase	and	
stearoyl-CoA	desaturase	[59].	SREBP-1	plays	an	integral	role	in	connecting		PI3K/AKT	signaling	
regulated	glucose	metabolism	and	Myc-regulated	glutamine	metabolism	to	lipogensis	[57].	In	
addition	to	regulating	several	cellular	processes,	such	as	membrane	biogenesis,		autophagy	
phagocytosis,	immunity	and		hypoxia	and	cell	cycle	[57].	In	healthy	tissues,	SREBPs	activation	
are	closely	regulated	by	intracellular	sterol	levels	via	negative	feedback	mechanism[59].		
1.4.2	SREBP-1	and	mTORCs	
SREBP-1	is	highly	expressed	in	cancers	[18-20].	Targeting	SREBP-1	through	genetic	and	
pharmacological	methods	has	also	demonstrated	significant	inhibition	of	tumor	cell	growth,	
which	proves	that	SREBP-1	is	a	potentially	promising,	if	novel,	molecular	target	in	cancer	
treatment.	SBREP-1	regulation	is	also	known	to	be	much	more	complex	in	cancer	cells.	Studies	
show	that	using	rapamycin	to	inhibit	mTORC1	has	a	diminutive	effect	on	SREBP-1	nuclear	
localization	and	its	transcriptional	level,	but	inhibiting	its	upstream	factors,	such	as	EGFR,	PI3K,	
and	Akt,	can	significantly	decrease	SREBP-1	activation	and	its	nucleus	localization	[60].	This	data	
suggests	that	other	oncogenic	molecules	outside	of	the	already	present	mTORC1	may	play	
important	roles	in	SREBP-1	regulation,	in	addition	to	the	above	mentioned	reason.	According	to	
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the	results	from	the	mTOR	kinase	inhibitor	Torin-1	[61]	(the	inhibitor	of	both	mTORC1	and	
mTORC2	activity),	mammalian	target	of	rapamycin	complex	2	(mTORC2)		may	also	play	
important	rule	in	stabilizing	the	nuclear	form	of	SREBP-1	[62].	These	results	also	show	a	
significant	decrease	in	SREBP-1	distribution	in	the	nucleus,	especially	in	comparison	to	mTORC1	
inhibitor	rapamycina	lone	[63].	Finally,	this	process	could,	at	least	in	part,	digress	and	reveal	the	
reason	that	targeting	mTORC1	has	had	an	incrementally	promising	response	in	clinics	using	
rapamycin	or	rapamycin	derivatives	in	cancer	treatment	[64].		Given	that	lipogenesis	is	an	
inextricable	source	in	the	formation	of	cellular	membranes,	cancer	cells	may	use	redundant	
cellular	pathways	to	regulate	the	expression	of	SREBP-1	and	its	activation,	in	order	to	guarantee	
that	cells	will	have	the	ability	to	obtain	enough	lipids	for	their	rapid	proliferative	processes.		
1.5.	Glioblastoma	multiforme	(GBM)	
1.5.1		The	cellular	origin	for	GBM		
GBM	develops	from	astrocytes,	star-shaped	glial	cells,	that	play	a	major	role	in	supporting	
nerve	cell	function.	Astrocytes	are	the	most	abundant	(20-40%)	glial	cell	in	the	CNS.	They	
perform	many	functions	including	regulating	electrical	impulses,	provide	glucose	and	lactate	to	
neurons,	facilitate	neuronal	repair	and	in	regulating	blood	flow	[65].	GBM	develops	primarily	in	
the	cerebral	hemispheres	with	95%	arising	in	the	supratentorial	region,	though	it	can	also	
develop	in	other	parts	of	the	brain,	brainstem,	or	spinal	cord	[66].GBM	has	rapid	and	enormous	
capacity	to	invade	neighbouring	brain	structures.	Histologically	GBM	is	quite	heterogeneous	
featuring	cystic	and	gelatinous	areas,	necrosis	and	multifocal	hemorrhage	[67].	GBM	tumors	are	
recognized	clinically	by	a	single,	relatively	large,	irregular	shaped	lesion	and	an	abnormal	
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vasculature	having	glomeroid	tufts	and	hyper	proliferative,	leaky	and	unorganized	blood	
vessels[68].	The	current	available	standard	medical	treatment	for	GBM	is	surgical	resection	
combined	with	ionizing	radiation	(IR)	and	chemotherapy		(temozolomide,	carmustine,	or	
lomustine)	[66].	This	treatment	is	not	sufficient	and	only	provides	a	very	minimal	extension	of	
survival	(12–14	month)	post-diagnosis	[68].	Thus,	novel	therapies	are	necessary	to	decrease	the	
morbidity	and	mortality	rate	of	patents	diagnosed	with	GBM.		
1.5.2	Brain	Tumour:	Statistics		
On	average,	an	individual	diagnosed	with	GBM	will	live	between	12	to	15	months,	where	the	
mean	incidence	rate	of	this	condition	is	3.19	in	100,	000	individuals	within	a	population.	
Temozolomide	(TMZ)	is	an	alkylating	agent	and	the	current	drug	of	choice	for	treating	GBM;	
however,	even	with	aggressive	treatment,	involving	radiotherapy	and	chemotherapy,	most	
patients	will	relapse.	Treatment	with	radiotherapy	and	surgery	has	a	dismal	3-	and	5-year	
survival	rate	of	4.4%	and	1.9%	respectively	[69].	The	addition	of	temozolomide	(chemotherapy)	
increased	the	3-	and	5-year	survival	rate	to	16%	and	9.8%	respectively	[69].	
1.5.3	Current	state	of	treatment	for	GBM	
The	genomic	instability,	high	proliferation	rate,	high	survivability	of	GBM	tumor	cells	and	the	
development	of	glioma	cancer	stem	cells	promotes	significant	resistance	to	current	therapeutic	
interventions	[68]		Dysregulation	of	critical	signal	transduction	pathways	is	critical	in	GBM	
propagation,	survival	and	metastasis.	Studies	have	shown	that	very	high	levels	of	6-
methylguanine	DNA	methyltransferase	(MGMT),	overactivity	of	PI3K/Akt	pathway,	over	
expression	of	EGFR,	CCL2/CCR2	axis,	hypoxia-inducible	factor-1	(HIF-1),	high	murine	double	
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minute	2	(Mdm2)	activity,	galactin-1	expression,	and	mutations	in	tumor	protein	p53	(P53)	and	
phosphatase	and	tensin	homolog		phosphatase	and	tensin	homolog	(PTEN)	
	oncogenes		play	important	roles	in	GBM	progression[70-71].	Current	studies	have	focused	on	
targeting	tumour-specific	genes	to	suppress	tumour	growth	[70-71].	Bevacizumab	is	a	
humanized	monoclonal	antibody	that	blocks	vascular	endothelial	growth	factor	(VEGF)	and	
suppresses	angiogenesis.	Bevacizumab		is	used	in	combination	therapy	for	GBM,	the	effects	
have	been	varied	or	inconclusive,	thus	concluding	bevacizumab	benefits	and	continued	use[72-
73].		EGFR	inhibitors	(nimouzumab	,	cetuximab,	dacomitinib)	have	been	also	been	used	in	
combination	therapy	for	GBM	and	results	were	also	varied	[74-75].	Because	GBM	is	a	highly	
dynamic	and	a	heterogenetic	tumor,	targeting	a	specific	gene	has	been	very	inefficient	as	a	
therapeutic	approach	due	to	the	ability	of	cancer	cells	to	compensate	for	disrupted	pathways.	
Thus,	targeting	a	global	system	may	lead	to	a	more	feasible	option	to	aid	in	the	design	of	
combinatorial	regimens.	
1.5.4	GBM	and	SREBP-1	
Recent	research	on	mechanisms	of	how	cancer	cells	grow	rapidly	and		sustain	themselves	
indicates	that	in	malignant	cells,	lipid	metabolism	undergoes	reprogramming	to	meet	high	
metabolic	demands	of	cancer	cells	and	the	lipogenic	phenotype	is	a	major	characteristic	of	
cancer.	Tumor	cells	even	divert	glucose	and	glutamate	metabolism	pathways	to	serve	in	lipid	
biogenesis	process.	SREBP-1	has	been	shown	to	be	a	major	part	of	many	other	cellular	
functions,	such	as	cell	size,	proliferation,	and	the	general	regulation	of	cell	cycle	[76].	Indeed,	
the	elevated	lipid	biogenesis	regulated	by	lipid	transcription	factor,	SREBP-1,	is	considered	a	
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major	characteristic	of	malignancies	including	GBM	[77-78].		In	GBM	and	many	other	cancer	
types,	SREBP-1	lipid	transcription	factor	and	its	downstream	gene	targets	are	upregulated/over-
activated	to	provide	much	needed	fatty	acids	and	phospholipids	in	order	to	promote	growth	
and	survival.	A	better	understanding	on	how	lipid	biogenesis	and	SREBP-1	contribute	to	
tumorigenesis	and	survival	of	cancer	cells	may	provide	new	strategies	for	cancer	treatment.				
HYPOTHESES		AND	RESEARCH	OBJECTIVE		
1.6			Hypothesis	and	The	aims	of	the	research		
1.6.1	Hypothesis		
Emerging	evidence	strongly	indicates	that	SREBP-1	is	a	potential	therapeutic	target	for	GBM.	
Targeting	SREBP-1	activation	seems	to	be	a	more	effective	anti-cancer	therapeutic	approach	
than	blocking	its	upstream	or	down-stream	targets	as	mentioned	in	the	introduction.	We	
therefore	hypothesize	that	“Indip”	,		small	molecule	“PF429242”	and	Fatostatin	by	inhibiting	
SREBP-1	activation	and	lipid	biogenesis	in	GBM	effectively	prevent	brain	tumor	proliferation,	
growth	and	decrease	survival	of	glioma	cells.		
1.6.2		Mechanism	of	Drug	Targets	and	Drug	actions	
1.		Indip	is	a	short	cell	penetrating	bioactive	TAT-fused	peptide,	which	can	directly	inhibit	
SREBP-1	activation	by	stabilizing	Insig1	an	endoplasmic	reticulum	(ER)	membrane	localized	
protein.	The	degradation	of	insulin-induced	gene-1	protein	(Insig-1)	is	required	for	SREBP-1	
activation.		
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2.	Fatostatin	inhibits	SREBP-1activation	by	binding	to	SCAP	and	inhibiting	SCAP’s	ability	to	
transport	SREBP-1	to	the	Golgi	apparatus.	
3.		PF429242	suppresses	SREBP-1	activation	by	inhibiting	Site-1	protease,	since	SREBP-1		is		
proteolytically	cleaved	by	the	Golgi	associated	Site-1	protease	and	Site-2	protease	in	order	to	
release	the-terminal	transcription	factor	domain	of	SREBP-1.	
1.6.3	The	aims	of	the	research	
1.	Determine	the	half	maximal	inhibitory	concentrations	(IC50)	of	“Indip”,	“PF429242”	and	"	
Fatostatin"	against	T98G	glioma	cell	line	and	tumor	stem	cell-like	cells	harvested	from	GBM	
patients.		
2.	To	investigate	therapeutic	effects	of	SREBP-1	inhibiters	by	examining	cell	viability,	
proliferation,	cell	cycle	arrest,	tumor	sphere	formation	and	migration	rate	when	compared	to	
the	vehicle	treated	T98G	glioblastoma	cells			
3.	To	investigate	the	effects	of	SREBP-1	inhibitors	on	SREBP-1	activation	and	the	expression	of	
its	target	genes	by	using	western	blot.		
4.	Investigating	possible	synergistic/additive	effects	of	combination	therapy	of	SREBP-1	
inhibitors	with	TMZ	in	tumor	cell	cultures		
CONCLUSION	AND	DISCUSSION	
1.7			General	conclusion	
1.7.1		Targeting	SREBP-1	to	treat	cancer	
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	 Targeting	metabolic	alterations	has	emerged	as	a	new	strategy	to	treat	cancer	in	the	
past	few	years.	For	example,	inhibiting	glycolysis	by	using	HK2	or	a	2-deoxyglucose	(2-DG)	
inhibitors,	both	of	which	have	shown	results	that	are	highly	promising,	at	least	in	a	pre-clinical	
model	[48,	75,	76].	It	has	also	been	proven	that	lipogenesis	appears	highly	activated	in	cancers	
and	interconnects	with	both	glutamine	and	glucose	metabolism	[17,	77,	78].	With	this	
information	taken	into	consideration,	the	suppression	of	fatty	acid	synthesis	could	offer	a	new	
take	on	blocking	tumour	growth.	SBREP-1	is	highly	expressed	in	glioblastoma	tissues	and	its	
over	activation	leads	to	activation	of	its	target	genes	[18].	Several	studies	have	shown	that	
Inhibition	of	ACC		and	FASN	activation	has	been	shown	to	suppress	cancer	cell	growth.	
Moreover,	Genetic	knockdown	or	pharmacological	inactivation	of	SREBP-1	and	ACL	have	been	
shown	to	significantly	impair	cancer	cell	growth	and	lead	to	cancer	cell	death	in	vitro	and	in	
vivo	[18].	SREBP-1	has	emerged	as	a	very	promising	drug	target	in	this	regard.	It	is	important	to	
factor	in	that,	in	normal	tissue,	SREBP-1	and	its	target	genes	are	usually	at	low	levels	of	activity	
and	expression,	as	opposed	to	the	high	levels	they	exhibit	in	cancer	cells.	Therefore,	the	specific	
targeting	of	SREBP-1-regulated	lipogenesis	pathways	could	have	an	incredibly	bright	future	as	a	
novel	approach	to	treat	cancer	and	malignant	tumor	growth.	
1.7.2		Conclusion	for	targeting	SREBP-1	to	suppress	the	GBM	growth	
	 Sterol	regulatory	element-binding	protein	1	(SREBP-1)	is	a	key	regulator	of	lipid	and	
cholesterol	biogenesis	and	has	been	linked	to	the	development	and	progression	of	glioblastoma	
multiforme.	Inhibition	of	SREBP-1	overactivation	by	fatostatin,	PF429242	or	indip	treatment	
resulted	in	significant	reduction	of	downstream	signaling	proteins.	In	addition,	these	inhibitors	
16		
decreased	tumor	size	and	induced	cell	cycle	arrest	at	the	G2/M	phase,	leading	to	apoptotic	cell	
death.	This	study	provides	evidence	that	SREBP-1	regulates	cyclin	dependent	kinase	5,	stearoyl-
CoA	desaturase	and	HMG-CoA	reductase	in	GBM	cells.		Further,	combination	treatment	
enhanced	the	anti-proliferative	effect	of	T98G	tumor	cells.	Thus,	it	is	evident	that	SREBP-1	
inhibitors	as	individual	or	in	combination	may	be	the	novel	therapeutic	intervention	in	the	
management	of	GBM.	Further,	treatment	of	GBM	cells	with	Indip/PF429242	has	an	additive	
effect	in	promoting	apoptosis	in	T98G	tumor	cells.	Taken	together,	these	findings	indicate	that	
combinational	drug	therapy	of	Indip/PF429242	has	an	enhanced	therapeutic	effect	over	
temozolomide.	Please	see	Chapter	two	for	more	details.	(	The	study	is	during	patent	approval	
process).		
1.7.3		Conclusion	for	targeting	SREBP-1	to	suppress	the	proliferation	of	MIA	PaCa-	2		cells		
		 Overactivation	of	SREBP1	and	elevated	lipid	biogenesis	are	considered	the	major	
characteristics	in	malignancies	of	prostate	cancer,	endometrial	cancer,	and	glioblastoma.	A	
recent	study	also	showed	that	inhibition	of	upstream	factors	such	as	EGFR,	PI3K	and	Akt	
drastically	reduced	expression	of	SREBP-1	in	cancer	cells	(60).	Sun	Y.	et	al	have	shown	a	clear	
correlation	of	SREBP1	levels	with	prognosis	in	pancreatic	cancers	(79).	However,	the	effect	of	
inhibition	of	SREBP1	on	pancreatic	cancer	cells	is	not	well	studied. The	present	study	examines	
the	effect	of	suppression	of	SREBP1	activation	by	its	inhibitors	like	fatostatin	and	PF429242	
besides	analyzing	the	impact	of	inhibitory	effects	on	SREBP1	downstream	signaling	cascade	in	
MIA	PaCa-2	pancreatic	cancer	cells.	Both	fatostatin	and	PF429242	inhibited	the	growth	of	MIA	
PaCa-2	cells	in	a	time	and	concentration-dependent	manner.	Further,	inhibition	of	SREBP1	
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overactivation	by	fatostatin	and	PF429242	leads	to	reduced	expression	of	its	downstream	
targets.	Our	in	vitro	data	suggest	that	SREBP1	may	contribute	to	pancreatic	tumor	growth	and	
its	inhibitors	could	be	considered	as	a	potential	target	in	the	management	of	pancreatic	cancer	
cell	proliferation.	Please	see	Chapter	three	for	more	details.	(The	study	was	published	on	
Biochemical	and	Biophysical	Research	Communications).		
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CHAPTER	2	
Pharmacological	effects	of	Sterol	regulatory	element-binding	protein	1	(SREBP-1)	inhibitors	
on	the	Glioblastoma	multiforme	brain	tumor	cells	–	A	Novel	Therapeutic	Approach	
ABSTRACT	
Glioblastoma	 multiforme	 (GBM)	 has	 been	 linked	 to	 aberrant	 fatty	 acid	 metabolism	 and	
overexpression	of	sterol	regulatory	element-binding	protein	1	(SREBP-1),	a	key	lipid	transcription	
factor.	In	the	present	study,	we	investigated	the	anti-tumor	effect	of	novel	SREBP-1	inhibitors	on	
glioblastoma	brain	tumor	cells.	 	Our	data	showed	that	the	direct	(fatostatin	and	PF429242)	or	
indirect	(Insig-1-derived	interference	peptide	[Indip])	SREBP-1	inhibitors	significantly	reduce	cell	
viability,	 proliferation	 and	 migration	 rate	 when	 compared	 to	 the	 vehicle	 treated	 T98G	
glioblastoma	cells.		Fatostatin,	Indip	and	PF429242	arrested	the	cell	proliferation	at	G2/M	phase.	
They	 impeded	 cell	 migration	 through	 CDK-5	 inhibition	 and	 induced	 apoptosis	 by	 increasing	
caspase-3	 activity.	 SREBP-1	 inhibition	 with	 fatostatin,	 Indip	 and	 PF429242	 also	 resulted	 in	
significant	suppression	of	downstream	lipogenesis	enzymes	like	stearoyl-CoA	desaturase-1	(SCD-
1),	fatty	acid	synthase	and	3-hydroxy-3-methylglutaryl-CoA	reductase	(HMGCoAR)	in	T98G	tumor	
cells.	In	addition,	the	combination	of	Indip	and	PF429242	treatment	had	the	greatest	effect	on	
suppressing	 cell	 growth	 (87%	 cell	 death),	 compared	 to	 individual	 treatments	 (40%	 and	 60%,	
respectively).	Our	findings	identify	the	anti-tumor	potential	of	SREBP-1	inhibitors	on	T98G	cells.	
Further,	combination	of	direct	and	indirect	treatment	enhances	its	effect	and	may	be	used	as	a	
novel	therapeutic	approach	for	the	treatment	of	GBM.	
INTRODUCTION		
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Glioblastoma	multiforme	 (GBM)	 is	 the	most	 common	 and	 deadliest	malignant	 primary	 brain	
tumor	of	the	central	nervous	system	(CNS),	referred	to	as	glioma1,	2.	GBM	is	considered	to	be	a	
rare	 tumor	 affecting	 0.1%	 of	 the	 population	 with	 a	 survival	 rate	 of	 12-14	 months	 and	 its	
incidences	 increased	 up	 to	 3%	 per	 year2,	 3.	 GBM	 are	 classified	 as	 Grade	 IV	 (most	 serious)	
astrocytoma	 according	 to	 the	 World	 Health	 Organization	 (WHO)	 tumor	 classification	 and	
accounts	 for	 more	 than	 60%	 of	 all	 brain	 tumors	 in	 adults4.	 Current	 drug	 therapy	 like	
temozolomide	(TMZ)	increased	the	3-	and	5-year	survival	rate	to	16%	and	9.8%,	respectively5.	
However,	 new	 reports	 indicate	 resistance	 to	 temozolomide	with	neurocognitive	 impairments	
and	novel	drugs	are	urgently	needed	to	enhance	patient	survival	and	quality	of	life	2.	
Dysregulation	of	critical	signal	transduction	pathways	has	been	reported	in	GBM	propagation,	
survival	and	metastasis.	Malignant	cells	have	been	found	to	increase	lipid	metabolism	to	meet	
the	energy	needs	of	highly	proliferating	tumor	cells6,7.	Tumor	cells	divert	glucose	and	glutamate	
metabolism	pathways	as	well	to	serve	in	lipid	biogenesis	process	and	signal	transduction	during	
tumor	progression8,9.	De	Novo	fatty	acid	synthesis	is	the	major	supply	of	fatty	acids	for	cancer	
cells,	 thus,	 enzymes	 involved	 in	 fatty	 acid	 metabolism	 have	 attracted	 major	 interest	 as	 a	
therapeutic	target	for	cancer	biology.	Studies	have	shown	that	inhibiting	fatty	acid	synthase	or	
lipogenesis	induces	cancer	cell	death10.	The	sterol	regulatory	element-binding	proteins	(SREBPs)	
have	gained	significant	 interest	as	a	possible	 therapeutic	 target	 for	cancer	 treatment.	SREBPs	
regulate	fatty	acid	and	cholesterol	biosynthesis11.	Elevated	lipid	biogenesis	in	GBM	is	regulated	
by	 lipid	 transcription	 factor	 sterol	 regulatory	 element-binding	 protein	 1	 (SREBP-1)12.	 In	many	
cancers	 and	 in	 particular	 GBM,	 SREBP-1	 and	 its	 downstream	 gene	 targets	 are	 upregulated	
promoting	lipid	biogenesis,	tumor	cell	growth	and	survival13.	A	better	understanding	on	how	lipid	
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biogenesis	and	SREBP-1	contribute	to	tumorigenesis	and	survival	of	cancer	cells,	may	provide	
new	strategies	for	cancer	treatment.				
Emerging	evidence	strongly	indicates	that	SREBP-1	is	a	potential	therapeutic	target	for	GBM14.	
Direct	inhibition	of	SREBP-1	activation	is	a	more	effective	approach	than	blocking	its	upstream	
or	down-stream	targets	for	inhibiting	lipid	biosynthesis	and	promoting	tumor	cell	apoptosis	
reducing	tumor	growth14.	In	addition,	high	SREBP	expression	is	associated	with	poor	prognosis	
of	GBM12.	Therefore,	inhibition	of	SREBP-1	could	be	a	potential	strategy	to	target.	In	this	study,	
the	activation	and	subsequent	maturation	of	the	SREBP-1	transcription	factor	was	targeted	
through	drug	treatments	using	Indip.	Indip	is	attached	to	a	trans-activator	of	transcription	(TAT)	
short	peptide	consisting	of	an	11	amino	acid	sequence.	These	peptides	have	shown	to	be	a	
prospective	method	of	drug	delivery	at	a	molecular	level	as	it	can	cross	biologically	
impermeable	membranes,	and	thus,	when	fused	to	potential	drug	treatments,	both	can	cross	
the	BBB	and	arrive	at	their	target.	Indip,	a	TAT-fused	short	peptide,	exhibits	prospective	use	in	
the	treatment	of	GBM	as	it	demonstrates	the	inhibition	of	SREBP-1	maturation	through	the	
prevention	of	Insig-1,	Insulin-induced	gene	1	protein,	ubiquitination	and	then	its	subsequent	
degradation,	which	further	inhibits	glioma	growth	and	survival.	We	have	previously	tested	Indip	
in	animal	models	of	stroke	and	ALS	and	have	shown	its	ability	to	pass	through	blood	brain	
barrier	(BBB)15,	16.	We	therefore	hypothesized	that	Indip	alone	or	in	combination	with	Fatostatin	
and/or	PF429242	(small	molecule	SREBP	inhibitors)	could	effectively	prevent	GBM	tumor	
proliferation,	growth	and	decrease	survival	of	glioma	cells	in	vitro	and	in	vivo.	Our	data	using	
the	T98G	GBM	cell	line	treated	with	Indip,	fatostatin	and	PF429242	confirms	effectiveness	of	
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this	therapeutic	approach	and	supports	inhibition	of	SREBP-1	as	a	potential	novel	therapeutic	
for	GBM.	
Mechanisms	of	Action	of	SREBPs	inhibitors	
	
(Adapted	from	Osherovich,	L.	SciBX	2(48);	10.1038/scibx.2009.1750	
	
RESULTS	
2.1.1		All	three	SREBP-1	inhibitors	inhibit	proliferation	in	a	dose-	and	time-dependent	manner.	
Glioblastoma	is	a	very	aggressive	cancer	in	part	to	the	high	proliferation	rate	of	the	cancer	cells.	
To	evaluate	whether	inhibition	of	sterol	regulatory	element-binding	protein	1	(SREBP-1)	activity	
promotes	a	decrease	in	T98G	cells	(Glioblastoma	cell	line)	proliferation,	we	carried	out	a	set	of	
assays	to	determine	whether	fatostatin	(inhibitor	of	SREBP-1),	PF429242	(reversible	inhibitor	of	
SREBP-1)	 and	 Indip	 (inhibitor	 of	 Insig-1	 degradation)	 inhibits	 T98G	 cell	 proliferation	 and	 the	
mechanism	involved.		
(IndiP) PF-
429242 
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The	T98G	cells	were	incubated	(1	x	105	cells/well)	in	tissue	culture	plates	and	allowed	to	attach	
and	 spread.	 The	 cells	were	 further	 incubated	with	media	 alone	or	with	 Indip	 (30-1,000	µM),	
fatostatin	 (2.5-100	µM),	 TMZ	 (60-2,000)	or	PF429242	 (2.5-100	µM)	 to	determine	 the	 IC50	 for	
proliferation	(figure	1a-d).	The	cells	were	incubated	for	24,	48	and	72	h	and	then	analyzed	for	
proliferation	using	 the	CCK-8	assay.	Fatostatin	and	PF459245	showed	a	more	potent	SREBP-1	
inhibition,	with	an	IC50	of	5	and	10	µM	respectively,	compare	with	Indip	and	TMZ,	with	an	IC50	of	
250	and	500µM	at	24	h,	respectively.	The	doubling	rate	for	T98G	cells	is	28	hrs	allowing	the	cells	
to	have	gone	through	one	doubling.	We	found	that	all	the	SREBP	inhibitors	significantly	reduced	
T98G	cell	proliferation	with	an	optimal	concentration	range	for	inhibitor	as	2.5-20	µM	fatostatin,	
10-40	µM	PF429242,	125-500	µM	Indip	and	250-1,000	µM	TMZ	(figure	1a-d).	
	Further,	we	determined	the	effect	of	these	inhibitors	on	T98G	cell	proliferation	over	time.	The	
GBM	cells	were	plated	in	tissue	culture	plates	allowed	to	adhere	and	spread.	The	cells	were	then	
incubated	in	10%-FBS-EMEM	alone	or	with	fatostatin	(5	µM),	PF429242	(10	µM)	or	Indip	(250	
µM)		for	8	days	at	37ºC	and	5%	CO2.		Each	day	the	cells	were	analyzed	for	cell	number	by	manually	
using	a	hemocytometer.	We	showed	that	both	fatostatin	and	PF429242	significantly	prevented	
proliferation	as	the	cell	population	hovered	around	1	x	104	cells,	initial	number	plated,	for	the	
duration	of	the	experiment	(figure	1e).		Both	5	µM	fatostatin	(FAT)	and	10	µM	PF429242	(PF)	has	
a	3-6	fold	decrease	in	the	number	of	T98G	cell	after	8	days	compared	to	untreated	(C).	However,	
250	 µM	 Indip	 (INDIP)	 did	 not	 significantly	 prevent	 proliferation	 of	 T98G	 cells	 after	 4	 days	
compared	 to	 untreated	 group	 (C).	 In	 addition,	 dansly	 fluorophore	 labeled	 Indip	 and	
immunofluorescence	staining	were	used	to	demonstrate	 that	 Indip	can	cross	cell	membranes	
with	facilitation	of	the	cell	penetrating	bioactive	TAT	as	mentioned	in	the	introduction	(Figure	
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1f).	 	Dansly	fluorophore	labelled	Indip	was	used	to	track	intracellular	localization	of	Indip.	The	
florescent	 antibody	 against	 insulin	 receptor	was	 used	 to	 enhance	 visual	 contrast.	 (Figure	 1f).	
Taken	together,	all	three	SREBP-1	inhibitors	inhibit	proliferation	in	a	dose-	and	time-dependent	
manner	and	treatment	with	PF429242	had	the	most	significant	long	term	antiproliferative	effect	
in	T98G	cells.				
To	 verify	 that	 fatostatin,	 PF429242	 and	 Indip	 inhibit	 SREBP-1	 activation	 and	 its	
downstream	 genes	 upregulation.	 Western	 blot	 analysis	 was	 preformed	 (figure	 2a-d).	 All	 3	
inhibitors	significantly	decreased	SREBP-1	activation	(figure	2a).	
2.1.2			Inhibition	of	SREBP-1	down	regulates	fatty	acid	and	cholesterol	synthesis	in	GBM	tumor	
cells.		
Fatty	 acid	 synthase	 (FAS),	 Stearoyl-CoA	 desaturase-1(SCD-1),	 and	 HMG-CoA	 reductase	
(HMGCoAR)	are	important	lipogenic	genes	regulated	by	SREBPs.	FAS	is	an	enzyme	that	mainly	
catalyzes	the	synthesis	of	palmitate	from	acetyl	CoA	and	malonyl	CoA;	whereas	SCD-1	catalyzes	
the	rate-limiting	step	in	the	formation	of	monounsaturated	fatty	acids	(MUFAs).	HMGCoAR	is	an	
enzyme	regulating	the	rate-limiting	step	in	cholesterol	synthesis.	
In	order	to	investigate	the	effect	of	SREBP1	inhibition	on	these	three	main	lipogenic	genes,	we	
measured	the	protein	expression	levels	of	FAS,	SCD-1,	and	HMGCoAR	in	T98G	tumor	cells	treated	
with	the	inhibitors.	The	T98G	cells	were	incubated	with	250	µM	Indip	(INDIP),	5	µM	fatostatin	
(FAT),	10	µM	PF429242	(PF)	for	48h	then	analyzed	for	FAS	by	Western	blot	(Fig.	2b).	All	the	three	
inhibitors	induced	a	decrease	(20	%	to	75%)	in	FAS	expression	(Fig.	2b).	PF429242	significantly	
reduced	(45%,	p<0.001,	n=3)	HMGCoAR	expression	compared	to	the	control	 (C)	 (Fig.	2c).	The	
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effects	of	Fatostatin	and	Indip	on	HMGCoAR	reduction	did	not	reach	to	a	significant	level	(Fig.	
2c).	As	shown	in	Fig	2d,	PF429242	drastically	decreased	SCD-1	expression	(80%,	p<0.001,	n=3)	
whereas	Indip	and	fatostatin	reduced	the	expression	by	(40-50%)	compared	to	that	of	the	control	
(Fig.	2d).		These	data	show	that	all	three	SREBP-1	inhibitors	inhibited	expression	of	both	FAS	and	
SCD-1;	only	treatment	with	PF429242	resulted	in	decreasing	expression	of	HMGCoAR.		
						2.1.3			Inhibition	of	SREBP-1	causes	G2/M	cell	cycle	arrest	and	caspase-mediated	apoptosis	
in	the	glioblastoma	cell	line	T98G.	
To	determine	the	percentage	of	cells	that	were	arrested	at	the	G2/M	cell	cycle	point,	T98G	cells	
were	incubated	in	10%-FBS-EMEM	alone	or	with	5	µM	fatostatin	(FAT),	10	µM	PF429242	(PF)	and	
250µM	Indip	(INDIP)	for	24,	48	and	72	hrs	at	37ºC	and	5%	CO2.	At	the	appropriate	time	point,	
cells	were	fixed	then	incubated	in	propidium	iodine	to	determine	cell	cycle	distribution	by	flow	
cytometry.	The	percent	of	cells	in	the	G0/G1,	S	and	G2/M	phase	was	determined	for	each	time	
point	(figure	3a-c).	 In	the	untreated	cells	(c)	only	5.5%	±	1%	were	arrested	in	the	G2/M	phase	
(figure	3d).	Treatment	of	the	cells	with	FAT	showed	the	most	significant	increase	in	cells	arrested	
in	the	G2/M	phase	(23%)	compared	to	control	(c)	at	48	hrs	(figure	3d).	Treatment	of	the	cells	with	
Indip	showed	the	lowest	percent	of	cells	(13%)	at	the	G2/M	phase	which	is	an	7%	increase	in	cells	
arrested	in	the	G2/M	phase	compared	to	control	(figure	3d).	Treatment	with	PF429242	had	an	
(6-12%)	increase	in	cells	arrested	at	the	G2/M	phase	at	the	48hr	time	point	and	2.25-fold	increase	
at	72hrs	compared	to	control	(figure	3d).	 	These	data	show	that	treatment	of	T98G	cells	with	
SREBP-1	inhibitors	decrease	cell	proliferation	and	this	decrease	is	due	impart	to	G2/M	cell	cycle	
arrest.		
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It	 has	 been	 shown	 in	 prostate	 cancer	 cells	 that	 fatostatin	 induces	 apoptosis	 through	 the	
activation	of	caspase-317.	We	therefore	investigated	whether	the	inhibition	of	SREBP-1	similarly	
induces	apoptosis	in	T98G	cells.	Cells	were	incubated	with	250	µM	Indip	(INDIP),	5	µM	fatostatin	
(FAT),	 10	 µM	 PF429242	 (PF)	 for	 24,	 48	 and	 72	 hrs.	 The	 cells	 were	 then	 measured	 by	 flow	
cytometry-based	propidium	iodine	(PI)	staining.	Treatment	of	T98G	cells	with	both	fatostatin	and	
PF429242	induced	significant	cell	death	(18-40%,	p<0.001,	n=3)	at	48	and	72	h	(Fig.	3e).	Whereas,	
Indip-treated	cells	only	had	a	small	effect	on	apoptosis	compared	to	fatostatin	and	PF429242.	
The	apoptotic	effects	of	fatostatin,	PF429242	and	Indip	appeared	to	be	time-dependent.	These	
data	indicate	that	inhibition	of	SREBP-1	promotes	apoptosis	in	glioblastoma	cells.		
To	 further	 define	 the	 underlying	mechanism	 for	 apoptotic	 cell	 death,	 we	 looked	 at	 caspase	
activation.	Cells	were	treated	with	250	µM	Indip	(INDIP),	5	µM	fatostatin	(FAT),	10	µM	PF429242	
(PF)	for	48	h	and	then	immunoblotted	for	active	caspase-3	(Fig.	3f).	Quantitative	analysis	showed	
that	both	PF429242	and	fatostatin	caused	a	significant	increase	in	caspase-3	activation	compared	
to	untreated	cells	(control)	(Fig.	3f).	Treatment	with	fatostatin	and	PF459245	increased	caspase	
activity	 by	 2.9	 and	 3.7	 fold	 (p<0.001,	 n=3),	 respectively	 whereas	 Indip	 treatment	 had	 no	
significant	effect.	Therefore,	the	inhibition	of	SREBP-1	triggers	the	apoptotic	cascade	pathway	at	
least	in	part	by	caspase-3	activation	in	glioblastoma	cells.					
						2.1.4	 	 	 Treatment	 of	 T98G	 glioblastoma	 cells	 with	 SREBP-1	 inhibitors	 modulates	 cell	
morphology	and	inhibits	Multicellular	Tumor	Spheroids	(MCTS)	growth.		
It	has	been	shown	that	T98G	cells	are	a	hyperpentaploid	cell	line	with	irregularly	shaped	nuclei	
and	are	 larger	 in	size	than	normal	astrocytes18.	 In	order	 to	determine	 if	 inhibition	of	SREBP-1	
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would	affect	cell	morphology	and	inhibit	the	growth	of	tumor	spheres,	T98G	cells	were	treated	
with	control	(C)	or	5	µM	fatostatin	(FAT),	10	µM	PF429242	(PF)	and	250	µM	Indip	peptide	(INDIP)	
for	72	h	at	37°C	and	5%CO2.	The	treated	cells	were	then	detached	with	trypsin	and	imaged	using	
phase	contrast	microscope.	The	untreated	cells	(C)	contained	a	significant	number	of	giant	cells	
(Fig.	4a).	Quantitative	analysis	of	cell	size	revealed	that	the	treatment	of	T98G	cells	with	Indip	or	
fatostatin	 significantly	 decreased	 the	 relative	 cell	 size	by	 35%	and	42%	 respectively	 (Fig.	 4b).	
Although	 compared	 to	 both	 fatostatin	 and	 Indip,	 the	 treatment	 with	 PF429242	 resulted	 in	
smaller	but	significant	reduction	(16%)	in	cell	size	(Fig.	4B),	however,	PF429242	altered	T98G	cell	
morphology	(Fig.	4A).		
We	also	investigated	the	ability	of	indip,	fatostatin,	PF429242	and	temozolomide	to	inhibit	the	
growth	of	MCST.	T98G	cells	were	grown	in	Matrigel	as	 indicated	in	Materials	and	Methods	to	
form	tumor	spheres19.	In	brief,	T98G	cells	were	suspended	in	Matrigel	(5.0	x	106	cells/ml)	then	
1.2	ml	was	plated	in	each	well	of	a	6-well	tissue	culture	plate	and	incubated	at	37°C	for	30	min.	
The	cells	were	further	incubated	in	media	alone	or	with	250	µM	Indip	(INDIP),	5	µM	fatostatin	
(FAT),	10	µM	PF429242	(PF)	and	500	µM	temozolomide	(TMZ)	then	incubated	for	7	and	14	days	
at	37°C	and	5%	CO2.	The	cells	were	imaged	by	phase	contrast	microscope	(Fig.	4c).	Quantitative	
analysis	 showed	 that	 at	 day	 7,	 fatostatin,	 PF429242	 and	 TMZ	 drug	 treatments	 had	 a	 similar	
decrease	 in	MCTS	 size	 (>35%)	 compared	 to	 untreated	 cells	 (C).	 In	 contrast,	 Indip	 had	minor	
effects	on	inhibiting	the	growth	of	MCST	(Fig.	4d).	At	day	14,	the	MCST	treated	with	PF429242	
showed	a	significant	decrease	(80%,	p<	0.001,	n=3)	in	tumor	size	compared	to	control	(Fig.	4c-
4d).	Both	TMZ	and	fatostatin	showed	a	significant	decrease	in	tumor	sphere	size	(60%	and	40%	
respectively,	p<	0.001,	n=3)	compared	to	control.	However,	Indip	failed	to	inhibit	the	growth	of	
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MCST	(Fig.	4c-4d).	 	Taken	together	these	data	 indicate	that	 inhibition	of	SREBP-1	reduces	the	
growth	of	 the	 T98G	 tumor	 sphere	 through	 in	 part	 by	 inhibiting	 cell	 proliferation.	 These	data	
indicate	that	SREBP-1	inhibition	can	significantly	inhibit	glioblastoma	growth.	
2.1.5	 Inhibition	of	SREBP-1	impedes	glioblastoma	cell	migration	through	down	regulation	of	
CDK-5	expression.		
The	ability	of	progressive	and	metastatic	cancer	cells	to	migrate	into	distant	regions	and	tissues	
is	one	of	the	hallmarks	to	disease	progression.	The	effects	of	fatostatin,	PF429242	and	Indip	on	
the	migration	of	T98G	cells	was	determined	using	a	scratch	assay.	A	denuded	area	was	made	in	
the	T98G	monolayer.	The	cells	were	incubated	in	media	alone	or	with	250	µM	Indip	(INDIP),	5	
µM	fatostatin	(FAT)	and	10	µM	PF429242	(PF)	for	72	h	at	37°C	and	5%	CO2.		Images	were	taken	
at	6-hour	intervals	from	zero	to	72	h.	The	migration	rate	of	the	cells	into	the	denuded	region	was	
determined.	After	72	h	treatment	with	PF429242	a	significant	reduction	(p<	0.001,	n=3)	in	cell	
migration	 rate	 was	 observed	 and	 the	 cells	 treated	 with	 PF429242	 had	 a	 76%	 decrease	 in	
migration	rate	compared	to	controls	(C)	(Fig.	5a-5b).	Treatment	with	fatostatin	and	Indip	resulted	
in	57%	and	25%	decrease	in	migration	rate,	respectively	(Fig.	5a-5b).	
It	appears	that	cyclin	dependent	kinase	5	(CDK-5)	expression	is	regulated	by	SREBP-1	and	involved	
in	 T98G	 cell	migration.	 Cyclin	 dependent	 kinases	 (CDK)	 are	well	 known	 to	 play	 a	 role	 in	 cell	
migration	 and	 have	 been	 identified	 to	 be	 involved	 in	 promoting	metastasis	 by	 reducing	 the	
activity	 of	 caldesmon20	 thus	making	 CDKs	 a	 target	 for	 glioblastoma	 therapy21.	 These	 studies	
linking	 CDK-5	 as	 a	 possible	 key	 mediator	 in	 cancer	 cell	 migration	 and	 metastasis	 led	 us	 to	
investigate	whether	the	inhibition	of	SREBP-1	could	affect	CDK-5	protein	expression.	Moreover,	
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the	inhibition	or	knockdown	of	CDK-5	have	been	shown	to	have	an	anticancer	effect	and	also	
synergizes	the	effectiveness	of	chemotherapeutic	agents	22.	T98G	cells	incubated	with	250	µM	
Indip	(INDIP),	5	µM	fatostatin	(FAT)	and	10	µM	PF429242	(PF)	were	analyzed	for	CDK-5	protein	
expression	by	Western	blot	(Fig.	5c).		Treatment	of	T98G	cells	with	PF429242	showed	a	significant	
decrease	(55%	p<0.001,	n=3)	 in	CDK-5	expression	compared	to	untreated	cells	(C)	(Fig.	5c).	 In	
contrast,	 both	 fatostatin	 and	 Indip	 had	 minor	 effects	 on	 CDK-5	 protein	 expression.	 This	
observation	suggests	that	the	inhibition	of	SREBP-1	down	regulates	the	expression	of	CDK-5	and	
may	play	a	role	in	the	mechanism	whereby	SREBP-1	inhibitors	prevent	cancer	cell	migration.		This	
finding	is	the	first	to	show	that	CDK-5	expression	is	regulated	by	SREBP-1	activity.			Blast	analysis	
revealed	that	potential	sterol	regulatory	element	(SRE)	and	EBOX	sequences	were	found	at	2-9	
and	3-9	positions	of	CDK-5	gene,	respectively,	with	100%	homology/similarity	which	warrants	
further	investigation.	
2.1.6	 	 	 	 	 	 	 	Combined	direct	and	 indirect	SREBP1	 inhibitors	enhanced	T98G	tumor	cell	death	
compared	to	individual	treatment.		
Most	cancers	occur	due	to	a	heterogeneous	biology	which	includes	multiple	genetic	change	or	
abnormalities,	disruption	of	multiple	signaling	pathways	and	cellular	heterogeneity31.	Therefore,	
it	 has	 been	 observed	 that	 single	 drug	 therapy	 is	 not	 sufficient	 to	 treat	 cancer	 effectively32.	
Presently,	combination	drug	regimens	are	a	standard	strategy	to	maximize	drug	efficacy	and	to	
reduce	cytotoxicity	for	normal	cells	33,	34.	Therefore,	we	investigated	whether	combinations	of	
SREBP-1	inhibitors	produce	a	synergistic	or	an	additive	effect	in	promoting	apoptosis.	T98G	cells	
were	incubated	with	different	combination	of	250	µM	Indip	(INDIP),	5	µM	fatostatin	(FAT),	10	
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µM	PF429242	(PF)	and	500	µM	temozolomide	(TMZ)	for	24,	48	and	72	h	and	then	analyzed	for	
viability.	As	shown	in	Fig.	6,	all	combinational	treatment	resulted	in	enhanced	cell	death	when	
compared	to	their	respective	individual	treatment.	The	combination	treatment	with	Indip	had	
the	greatest	effect	on	promoting	cell	death	(Fig.	6a-6c).		Indip/PF429242	treatment	caused	87.5%	
tumor	 cell	 death.	 	 This	was	 a	 5-fold	 increase	 compared	 to	 Indip	 alone	 and	 a	 3-fold	 increase	
compared	to	PF429242	alone	(Fig.	6c).	The	combinations	of	Indip/TMZ	and	Indip/fatostatin	were	
also	 effective	 in	 inducing	 cell	 death	 compared	 to	 the	 individual	 compounds	 (37%	 and	 15%,	
respectively)	(Fig.	6c).		In	addition,	combination	of	PF429242/fatostatin	and	PF429242/TMZ	has	
similar	percentage	of	apoptosis	(Fig.	6f).	Similar	results	for	the	combination	treatment	were	also	
observed	at	24	and	48	h	time	points	(Fig.	6a,	6b,	6d	and	6e).		Collectively,	these	results	indicate	
that	 combination	 therapy	 may	 be	 more	 efficient	 at	 eliciting	 an	 apoptotic	 effect	 than	 the	
individual	treatment.	Moreover,	inhibition	of	Insig-1	degradation	and	inhibition	SREBP-1	activity	
additively	exhibits	the	greatest	efficacy	for	inducing	apoptosis.	These	findings	provide	a	rationale	
for	the	development	of	novel	therapies	for	GBM.	
2.2.1				
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Figure.1	 Time	 and	 concentration-dependent	 effects	 of	 Indip,	 fatostatin,	 PF429242	 and	
Temozolamide	(TMZ)	on	percentage	(%)	cell	proliferation	in	T98G	cells.	
Indip,	Fatostatin,	PF429242	and	Temozolamide	inhibited	the	proliferation	of	T98G	cells	in	a	time-	
and	 dose-dependent	 manner.	 	 T98G	 cells	 were	 incubated	 with	 increasing	 concentrations	 of	
inhibitor,	incubated	for	24	h,	48	h,	and	72	h	and	then	cells	were	assayed	for	proliferation	using	
the	CCK-8	assay.	The	values	are	represented	as	percentage	cell	proliferation.	where	the	vehicular	
control	groups	(C)	were	considered	as	100%,	(a)	Indip	(0	to	1,000	μM),	(b)	fatostatin	(0	to	100	
μM),	(c)	Temozolomide	(0	to	2,000	μM),	(d)	PF429242	(0	to	100	μM).	(e)	Fatostatin	and	PF429242	
significantly	impeded	proliferation	of	T98G	cells	over	time.	Treatment	with	Indip	had	only	a	minor	
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effect	on	inhibiting	cell	proliferation	after	4	days.		T98G	cells	were	incubated	with	250	µM	Indip	
(INDIP),	Fatostatin	5	µM	(FAT)	and	PF429242	10	µM	(PF)	for	8	days.	Proliferation	was	determined	
by	cell	count.	(f)	T98G	cells	were	incubated	with	dansyl	fluorophore	labeled	Indip	for	2	hrs	and	
then	 incubated	 with	 anti-inulin	 receptor	 antibody,	 followed	 by	 incubating	 with	 Alexa	 Fluor	
conjugated	 secondary	antibody	 for	 fluorescent.	Dansyl	 Fluorophore	 labeled	 Indip	 is	 shown	 in	
blue	and	insulin	receptor	reference	in	green.	Images	were	taken	using	laser	scanning	microscopy	
with	 100X	 magnification.	 Each	 point	 represents	 mean	 ±	 SEM	 (n=3)	 values.	 The	 values	 were	
measured	using	 one	way	Anova	 followed	by	 tukey’s	multiple	 comparison	 test	 as	 post	 hoc	 in	
Graphpad	Prism		version	6.0.	**	and	#	indicates	P	value	<	0.01	and	0.001,	respectively	vs	vehicular	
control.	Each	point	represents	mean	±	SEM	(n=3)	values.	The	values	were	measured	using	one	
way	Anova	followed	by	tukey’s	multiple	comparison	test	as	post	hoc	in	Graphpad	Prism		version	
6.0.	**	and	#	indicates	P	value	<		0.01	and	0.001,	respectively	vs	vehicle	control.	
2.2.2	
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Figure.2	Inhibition	of	SREBP-1	reduces	fatty	acid	synthesis	by	hindering	SCD-1	and	HMGCoAR	
expression.			
Western	 blot	 analysis	 of	 sterol	 regulatory	 element	 binding	 protein	 1	 (SREBP1)	 and	 its	
downstream	 signaling	 proteins	 on	 250	 µM	 Indip	 (INDIP),	 5	 µM	 Fatostatin	 (FAT)	 and	 10	 µM	
PF429242	 (PF)	 exposed	 T98G	 glioblastoma	 cells	 after	 48	 h	 incubation.	 Untreated	 cells	 were	
incubated	without	 inhibitors	(C).	Representative	western	blots	of	SREBP1	and	 its	downstream	
signaling	proteins	along	with	loading	control	(β-actin)	were	shown.		(a)	ACTIVE-SREBP-1,	(b)	fatty	
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acid	 synthase,	 (c)	 Hydroxymethylglutaryl-CoA	 reductase	 (HMGCoAR),	 (d)	 Stearoyl-CoA	
desaturase	(SCD-1),	(e)	 Insulin	 induced	gene-1	(Insig-1).	Values	were	expressed	in	mean±SEM,	
n=3	and	similar	results	were	obtained	in	three	individual	experiments.	Mean	difference	between	
the	 exposure	 time	 was	 measured	 using	 one-way	 ANOVA	 followed	 by	 Tukey’s	 multiple	
comparison	test	as	post	hoc	in	Graphpad	Prism		version	6.0.	*,	**	and	#		indicates	P	value	<	0.05,	
0.01	and	0.001,	respectively	vs	control	(C).		
2.2.3
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Figure.3	 Inhibition	 of	 SREBP-1	 promoted	 cell	 cycle	 arrest	 in	 the	 G2/M	 phase	 and	 induced	
caspase-mediated	apoptosis	in	glioblastoma	cancer	cells.		
	Cells	were	incubated	with	250	µM	Indip	(INDIP),	5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	
for	24	h,	48	h	and	72	h.	Cell	cycle	phase	was	determined	by	flow	cytometry	based	PI-staining	and	
quantitated	by	FloJo	software.	Graph	represents	percentage	cell	cycle	arrest	(G2/M,	S	and	G1/M	
phase	cell	cycle)	of	Indip,	fatostatin	and	PF429242	at	24	h	(a),	48	h	(b)	and	72	h	(c),	respectively.	
(d),	Determination	of	G2/M	phase	arrest	in	T98G	cells	on	exposure	with	250	µM	Indip	(INDIP),	5	
µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	at	various	time	periods.	(e),	250	µM	Indip	(INDIP),	
5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	induce	apoptotic	cell	death	in	T98G	glioblastoma	
cells.	 Percentage	 of	 apoptotic	 cell	 death	 was	 measured	 at	 various	 time	 points	 using	 flow	
cytometry	 based	 PI-staining	 and	 quantitated	 by	 FloJo	 software.	 (f),	 Caspase-3	 activity	 was	
determined	by	western	blot.	5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	increased	active-
caspase	 expression	by	 2.9	 and	3.7	 fold,	 respectively.	However,	 treatment	with	 250	µM	 Indip	
(INDIP)had	no	significant	effect	on	activating	caspase-3.	Values	were	expressed	in	mean±SEM,	
n=3	and	similar	results	were	obtained	in	three	individual	experiments.	Mean	difference	between	
the	exposure	time	was	measured	using	one	way	ANOVA	followed	by	tukey’s	multiple	comparison	
test	as	post	hoc	in	Graphpad	Prism		version	6.0.	*,	**	and	#	indicates	P	value	<	0.05,	0.01	and	
0.001,	respectively	vs	control.	
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2.2.4	
	
	
Figure.4	Evaluation	of	cytotoxicity	on	cell	size	and	multicellular	tumor	spheroid	(MCTS)		
Inhibition	of	SREBP-1	reduced	cell	size	and	MCTS	growth.	T98G	cells	were	incubated	with	250	µM	
Indip	(INDIP),	5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	for	72hrs	and	then	the	diameter	
of	 each	 T98G	 cell	 was	 measured	 by	 Phase-contrast	 microscopy	 at	 10x	 magnification	 after	
detaching	 the	 cells	with	 trypsin	 and	 2D	 surface	 area	 of	 cells	were	 quantified.	 (a),	 T98G	 cells	
images	produced	by	Phase-contrast	microscopy	after	72	hr	 incubation	 Indip,	 (b),	Quantitative	
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analysis	of	the	cell	size	after	 incubating	with	the	SREBP	inhibitors.	 Indip,	Fatostatin,	PF429242	
and	Temozolomide	 impeded	MCTS	 formation	and	growth	 in	T98G	cells.	 (c),	The	 formation	of	
MCTS	from	T98G	cells	after	7	and	14	days	incubation.	A	phase-contrast	microscopy	was	used	to	
monitor	 the	MCTS	 formation	 and	growth.	 (b),	 The	diameter	of	 each	MCTS	was	measured	by	
phase	contrast	microscopy	at	4X	magnification	and	2D	surface	area	of	MCTS	was	calculated.	T98G	
cells	were	cultured	in	EMEM	with	Matrigel	and	then	treated	with	250	µM	Indip	(INDIP),	5	µM	
Fatostatin	 (FAT),	 10	µM	PF429242	 (PF)	 and	500	µM	Temozolomide	 (TMZ)	 for	 7	 and	14	days.	
Values	were	expressed	in	mean±SEM,	n=3	and	similar	results	were	obtained	in	three	individual	
experiments.	Mean	difference	between	the	exposure	time	was	measured	using	one-way	ANOVA	
followed	by	Tukey’s	multiple	comparison	test	as	post	hoc	in	Graphpad	Prism		version	6.0.	*	and	
#	indicates	P	value	<	0.05	and	0.001,	respectively	vs	control.	
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2.2.5		
	
Figure.	5	SREBP-1	inhibition	significantly	impeded	the	ability	of	T98G	cells	to	migrate	
Determination	of	the	relative	migration	rate	(distance	traveled)	by	T98G	cells	into	the	acellular	
region	on	250	µM	Indip	(INDIP),	5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	exposure	using	
scratch	assay.	(a)	Cell	migration	was	photographed	at	0	and	72	h	later.	(b)	Quantitative	analysis	
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of	 the	 cellular	 migration	 rate	 after	 72	 h.	 	 (c)	 The	 decrease	 in	 T98G	 migration	 was	 through	
inhibition	of	CDK-5.	Cells	were	treated	with	250	µM	Indip	(INDIP),	5	µM	Fatostatin	(FAT)	and	10	
µM	PF429242	 (PF)	 for	 48	h	 then	Western	blotted	 for	 CDK-5.	Untreated	 cells	were	 incubated	
without	 inhibitors	 (C).	 Values	 were	 expressed	 in	 mean±SEM,	 n=3	 and	 similar	 results	 were	
obtained	 in	 three	 individual	 experiments.	 Mean	 difference	 between	 the	 exposure	 time	 was	
measured	using	one	way	ANOVA	followed	by	Tukey’s	multiple	comparison	test	as	post	hoc	 in	
Graphpad	Prism		version	6.0.	*,**	and	#	indicates	P	value	<	0.05,	0.01	and	0.001,	respectively	vs	
control.		
2.2.6			
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Fig.6.	 Treatment	 with	 Indip,	 fatostatin,	 PF429242	 and	 TMZ	 have	 an	 additive	 effect	 on	
suppressing		proliferation	of	T98G	cells.	
Cytotoxicity	 assay	of	drug	 combinations	250	µM	 Indip	 (INDIP),	 5	µM	Fatostatin	 (FAT),	 10	µM	
PF429242	(PF)	and	500	µM	Temozolomide	(TMZ)	in	T98G	cells.	The	cells	were	then	analyzed	for	
cell	death	by	CCK-8	assay.	Graph	represents	the	percentage	viable	cells	at	(a)	24	h,	(b)	48	h,	(c)	
72	h,	(d)	24	h,	(e)	48	h	and	(f)	72	h	exposure	period.	Values	were	expressed	in	mean±SEM,	n=3	
and	similar	results	were	obtained	in	three	individual	experiments.	Mean	difference	between	the	
exposure	time	was	measured	using	one	way	anova	followed	by	tukey’s	multiple	comparison	test	
as	post	hoc	in	Graphpad	Prism		version	6.0.	*,**	and	#	indicates	P	value	<	0.05,	0.01	and	0.001,	
respectively	vs	control.		
2.2.7	
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Figure.7	 Time	 and	 concentration-dependent	 effects	 of	 Indip,	 fatostatin,	 PF429242	 and	
Temozolamide	(TMZ)	on	percentage	(%)	cell	proliferation	in	the	rat	glial	cells.	
Indip,	Fatostatin,	PF429242	and	Temozolamide	 inhibited	the	proliferation	of	rat	glial	cells	 in	a	
time-	and	dose-dependent	manner.	Rat	glial	cells	were	incubated	with	increasing	concentrations	
of	inhibitor,	incubated	for	24	h,	48	h,	and	72	h	and	then	cells	were	assayed	for	proliferation	using	
the	CCK-8	assay.	The	values	are	represented	as	percentage	cell	proliferation.	where	the	vehicular	
control	groups	(C)	were	considered	as	100%,	(a)	Indip	(0	to	500	μM),	(b)	fatostatin	(0	to	80μM),	
(c)	Temozolomide	(0	to	1,000	μM),	(d)	PF429242	(0	to	80	μM).	Each	point	represents	mean	±	SEM	
(n=3)	 values.	 The	 values	 were	measured	 using	 one	 way	 Anova	 followed	 by	 tukey’s	 multiple	
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comparison	test	as	post	hoc	in	Graphpad	Prism		version	6.0.	**	and	#	indicates	P	value	<	0.01	and	
0.001,	 respectively	vs	vehicular	 control.	Each	point	 represents	mean	±	SEM	(n=3)	values.	The	
values	were	measured	using	one	way	Anova	followed	by	tukey’s	multiple	comparison	test	as	post	
hoc	in	Graphpad	Prism		version	6.0.	**	and	#	indicates	P	value	<		0.01	and	0.001,	respectively	vs	
vehicle	control.	
	
MATERIALS	AND	METHODS	
Material	and	Methods	
2.3.1		Cell	Culture.		
T98G	Glioblastoma	cell	lines	were	obtained	from	American	Type	Culture	Collection	(ATCC®CRL-
1690TM	).	Cells	were	grown	as	monolayer	in	cell	culture	flasks	with	EMEM	media	(HyClone,	Cat#	
SH30024.01)	containing	10%	(v/v)	fetal	bovine	serum	(FBS)	(HyClone,	Cat#SH30070.01)		
2.3.2		Cytotoxicity.	
	Cytotoxicity	assay	of	T98G	cells	was	performed	by	using	CCK-8	Assay	kit	(Dojindo:	CK04-11)	as	
indicated	by	manufactures	protocol.	Mono	layers	of	T98G	cells	were	grown	in	10%	FBS-EMEM	in	
96-well	 plate	 (5,000	 cells/well)	 overnight	 at	 37°C	 and	 5%CO2.	 The	 media	 was	 removed	 and	
replace	with	100	ml	of	10%	FBS-EMEM	media	with	or	without	without	Indip	(BIOMATIK,	Cat	#	
11290),	fatostatin	(TOCRIS	BIOSCIENCE,	Cat	#	4444),	PF429242	(Sigma,	Cat	#	SML0667)	or	TMZ	
(Sigma,	Cat	#	T2577)	as	 indicated	in	results	and	incubated	at	37°C	and	5%CO2.	The	cells	were	
47		
incubated	at	various	time	intervals	(24h,	48h	and	72h),	then	10	μl	of	CCK-8	solution	was	added	
to	each	well	and	incubated	for	2h	at	37°C	and	5%CO2.	The	samples	were	analyzed	for	soluble	
formazan	 produced	 using	 a	 SpectraMax	M5	 plate	 reader	 at	 450	 nm	 (Molecular	 Devices).	 All	
samples	were	performed	in	triplicate.	The	mean	of	each	sample	was	determined.	
2.3.3		Western	blotting.	
	T98G	cells	were	plated	in	10	cm	petri	dishes	and	incubated	in	10%	FBS-EMEM	media	at	37°C	and	
5%CO2.	 After	 overnight	 attachment,	 the	 cells	 were	 treated	 with	 either	 vehicle	 (control),	
PF429242,	Indip	or	fatostatin	for	48	hours.	The	concentrations	of	fatostatin,	Indip	and	PF429242	
employed	were	 chosen	based	on	 the	 IC50	 values	 derived	 from	preliminary	 studies.	 	For	 total	
protein	extraction,	cells	were	lysed	in	RIPA	buffer	(20	mM	Tris-HCl	pH	7.5,	150	mM	NaCl,	1	mM	
Na2EDTA,	1	mM	EGTA,	1%	NP-40,	1%	sodium	deoxycholate,	2.5	mM	sodium	pyrophosphate,	1	
mM	b-glyceroposphate,	1	mM	Na3VO4,	1	µg/ml	leupeptin)	supplemented	with	protease	inhibitor	
cocktail	(Cell	Signaling,	#5871).			Total	protein	extracts	were	quantified	using	the	Bradford	assay	
with	bovine	serum	albumin	as	standard.	Western	blot	experiments	were	carried	out	using	the	
Mini	Trans-Blot	cell	BIO-RAD.	The	following	primary	antibodies	were	used:	anti-SCD1	(Abcam,	
ab19862;	dilution	1:1000),	anti-CDK5	(Abcam,	ab715Y;	dilution	1:1000),	anti-	HMGCoAR	(Abcam,	
ab174830;	dilution	1:1000),	anti-SREBP1	(Santa	Cruz,	sc-365513,	1:500),	anti-fatty	acid	synthesis	
(Abcam,	ab22759;	dilution	1:1000)	and	anti-caspase-3	 (Cell	 signalling,	#9662;	dilution	1:1000)	
Anti-β	actin	(Abcam,	ab8227;	dilution	1:1000)	was	used	for	normalization.		All	the	experiments	
were	performed	in	triplicate.	
2.3.4		Flow	cytometry.		
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Cells	were	seeded	 in	6-well	plates	(1	X	105	cells/well),	 incubated	overnight	 in	10%	FBS-EMEM	
media	at	37ºC	and	5%CO2.	The	media	was	removed	and	replaced	with	10%	FBS-EMEM	media	
containing	SREBP-1	inhibitors	as	indicated	in	the	results	section.	The	cells	were	further	incubated	
at	37°C	and	5%CO2	for	24,	48	and	72	hrs.	At	the	specified	time	points,	cells	were	trypsinized,	
harvested,	fixed	in	ice	cold	70%	ethanol-PBS	for	10	min	and	then	stored	at	4ºC	until	further	use.	
For	analysis,	the	cells	were	removed	from	the	-20ºC	storage	and	incubated	on	ice	for	15	min.	
Cells	were	washed	 in	 ice	 cold	PBS	X	2	 times	and	 then	 incubated	 in	 staining	buffer	 (60	μg/ml	
propidium	 iodide;	Sigma-P4170	and	0.15	mg/ml	RNase	A;	Sigma-R6513)	 for	20	min.	 For	each	
sample	~1	million	gated	cells	were	analyzed	by	the	flow	cytometry	(BD-FAC	ScaliburTM	).	Data	
analysis	was	preformed	using	FlowJo	software	(FlowJo,	LLC).	All	samples	were	run	in	triplicate.	
2.3.5		Multicellular	Tumor	Spheroids	(MCTS)	culture	and	analysis:		
The	MCTS	culture	has	been	adapted	from	Lee	et	al20.	In	brief,	coating	of	the	6	well	plates	was	
performed	 by	 adding	 120	 µl/well	 of	 Matrigel	 (Sigma,	 E1270),	 then	 spreading	 evenly	 on	 the	
surface	 with	 a	 pipette	 tip.	 The	 coated	 plates	 were	 incubated	 at	 37°C	 for	 15	 min.	 	 T98G	
Glioblastoma	cells	were	trypsinized	into	a	single	cell	suspension.	The	cells	were	centrifuged	at	
115	x	g	for	5	min	at	4ºC	and	then	the	supernatant	was	removed.	The	cells	were	resuspended	in	
ice	cold	Matrigel	(5.0	x	106	cells/ml).	The	T98G	cells	were	plated	on	Matrigel	coated	6-well	TC	
plates	(1.2	ml/well)	and	incubated	at	37ºC	for	30	min.	To	each	well,	3	ml	of	10%	FBS-EMEM	media	
was	added	with	or	without	inhibitors	as	indicated	in	results.	The	cells	were	incubated	for	14	days	
at	37°C	and	5%CO2	and	the	media	was	changed	every	2	days.	At	day	7	and	14,	the	tumor	spheres	
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were	 imaged	 on	 a	 phase	 contrast	 microscopy	 (OLYMPUS,	 IX71)	 at	 4X	 magnification.	 Tumor	
sphere	size	was	analyzed	using	ImageJ	software.			
2.3.6		Scratch	Assay.	
	T98G	 cells	were	 grown	 in	 10%	FBS-EMEM	media	 in	 a	 6	wells	 plate	with	or	without	 SREBP-1	
inhibitors	as	indicated	in	results	and	incubated	at	37°C	and	5%CO2.	The	monolayer	was	scrapped	
with	a	p200	pipette	tip	to	make	a	denuded	area.	The	debris	was	removed	and	the	cells	were	
washed	once	with	1	ml	of	the	10%	FBS-EMEM	media	to	remove	additional	dislodged	cells.	The	
cells	were	then	incubated	with	10%	FBS-EMEM	media	with	inhibitors	as	indicated	in	results	for	
72	h	at	37°C	and	5%CO2.	Each	flask	was	marked	so	that	the	same	reference	area	was	imaged	up	
to	72	h	with	6	h	interval.	The	denuded	area	was	imaged	using	a	phase	contrast	microscope	using	
a	 4x	 objective	 lens.	 The	 relative	 distance	 traveled	 by	 the	 cells	 into	 the	 acellular	 region	 was	
determined	using	ImageJ	software.	Cells	treated	with	diluent	were	used	as	a	baseline	control.	
2.3.7	 	 Immunofluorescence	 staining	 and	 Fluorescence	 Studies	 of	 Labeled	 Indip	 Containing	
Dansyl	Fluorophore.		
Immunostaining	 was	 adopted	 from	 Abcam	 protocol.	 Briefly,	 coverslips	 were	 coated	 with	
polyethylineimine	 for	 5	 min	 at	 room	 temperature.	 Then	 T98G	 cells	 were	 cultured	 on	 glass	
coverslips	at	37°C	and	5%	CO2	after	 rinsing	 the	coverslips	 in	PBS	three	times.	After	overnight	
incubation,	T98G	cells	were	incubated	with	5-N,N-dimethylaminonaphthalene	sulfonyl	(dansyl)	
fluorophore	labelled	Indip	(BIOMATIK,	Cat	#	523525)	for	2	h.	Next,	the	cells	were	fixed	in	10%	
formalin	for	10	min	after	briefly	washing	three	times	in	PBS.		To	block	unspecific	epitopes,	T98G	
cells	were	incubated	with	2%	BSA,	23mg/mL	glycine	in	PBST	for	1	h.	Then	the	cells	were	incubated	
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in	the	diluted	primary	antibody	in	2%	BSA	(in	PBST)	for	overnight	at	4	oC	(Anti-Insulin,	Abcam,	
ab18147;	 dilution	 1:	 500),	 followed	 by	 incubating	 with	 anti-rabbit	 ALexa	 Fluor	 488	 (Abcam,	
ab150077;	dilution	1:	500).	Finally,	the	cell	images	were	analyzed	the	laser	scanning	microscopy	
(ZEISS,	LSM	700).		
2.3.8		Isolation	of	mouse/rat	astrocyte.	
	All	procedures	on	these	animals	were	performed	in	accordance	with	and	after	have	approved	by	
the	 institutional	animal	care	and	use	committee	(IACUC)	of	University	of	Saskatchewan.	 	Rats	
were	anaesthetized	with	isoflurane	then	euthanized	by	decapitation.	The	tissue	was	washed	in	
70%	ethanol.	The	brain	was	removed	and	the	meninges	were	removed	from	the	cerebral	cortex.	
The	brain	tissue	was	washed	in	Hank’s	balanced	salt	solution.	Tissue	digestion	was	performed	by	
incubating	 in	 trypsin-EDTA	 (Gibco)	 for	 15	 min	 at	 37ºC.	 The	 digestion	 was	 stopped	 with	 the	
addition	of	500µl	of	FBS	(HyClone).	The	cell	suspension	was	centrifuged	for	1	min	at	300	xg	and	
the	supernatant	was	removed.	The	cells	were	resuspended	in	10	ml	of	astrocyte	growth	media	
(high	glucose-DMEM	(HyClone),	10%	FBS	(HyClone),	1%	penicillin/streptomycin	(Sigma-Aldrich))	
and	mixed	by	pipetting	to	dissociate	the	cells.	The	cell	suspension	was	placed	in	a	T75	flask	then	
incubated	at	 37ºC	and	5%CO2	 for	48	hr.	 The	media	was	 replaced	 to	 removed	dead	 cells	 and	
repeated	every	3	days	until	the	flask	was	confluent.	Once	confluent,	the	flask	was	placed	on	an	
orbital	shaker	and	shaken	at	180	rpms	for	30	min	at	37ºC	and	5%CO2	to	remove	microglia.	The	
media	was	removed	and	replace	with	astrocyte	growth	media.	The	flask	was	placed	back	on	the	
rotator	 an	 shaken	 at	 240	 rpms	 overnight	 at	 37ºC	 and	 5%	 CO2	 to	 remove	 oligodendrocyte	
precursor	 cells.	 The	 media	 was	 removed	 and	 the	 cells	 were	 washed	 with	 PBS	 (Gibco).	 The	
51		
adherent	astrocytes	were	further	incubated	in	astrocyte	growth	media	at	37ºC	and	5%	CO2	until	
confluent.	
	
2.3.9		Statistical	Analysis.	
	All	 the	 statistical	 analyses	 were	 conducted	 using	 Graphpad	 Prism	 	 6	 software	 (GraphPad	
Software,	 San	Diego,	 CA).	 Kaplan-Meyer	 survival	 curves	were	 compiled	 using	 Prism	 software	
(GraphPad).	Tumor	sphere	size,	cell	cycle,	proliferation	and	cell	migration	were	compared	by	one-
way	 ANOVA	 test.	 Additional	 experiments	 were	 analyzed	 by	 the	 unpaired	 t-test.	 Data	 are	
presented	as	mean	±	standard	deviation	(SD).	P	<	0.05	was	considered	statistically	significant.	
DISCUSSION		
The	 present	 study	 clearly	 showed	 that	 active	 form	 of	 SREBP-1	 and	 its	 downstream	 signaling	
proteins	were	increased	in	T98G	tumor	cells.	Inhibition	of	SREBP-1	overactivation	by	fatostatin,	
PF429242	or	indip	treatment	resulted	in	significant	reduction	of	downstream	signaling	proteins.	
In	addition,	these	inhibitors	decreased	GBM	cell	line	tumor	size	and	induced	cell	cycle	arrest	at	
G2/M	phase,	leading	to	apoptotic	cell	death.	Further,	combination	treatment	enhanced	the	anti-
proliferative	effect	of	T98G	tumor	cells.	Thus,	it	is	evident	that	SREBP-1	inhibitors	as	individual	or	
in	combination	may	be	a	novel	therapeutic	intervention	in	the	management	of	GBM.	
SREBP-1	regulates	fatty	acid	biosynthesis.	Insig-1 levels raise with the addition of Indip and 
subsequent inhibition of the activation of the SREBP-1 lipid transcription factor as the 
transcription factor cannot escape the membrane. We	demonstrated	that	the	inhibition	of	
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SREBP-1	resulted	in	suppression	of	three	major	downstream	targets:	FAS,	SCD-1	and	HMGCoAR.	
SREBP-1	regulation	of	fatty	acid	synthase	and	SCD-1	has	been	observed	in	breast,	pancreatic	
and	prostate	cancers	and	inhibition	of	SREBP-1	promoted	cancer	cell	death13,17,35.		Thus,	SREBP-
1	may	prove	to	be	a	central	mechanism	for	tumor	cell	survival.	This	correlates	with	our	present	
findings.	CDK-5	is	a	key	kinase	in	neural	maturation	and	migration,	regulating	the	reelin	
signaling	chain	and	synaptic	vesicle	exocytosis,	which	are	key	processes	in	neuronal	function23-
25.	The	decreased	expression	of	CDK-5	in	our	present	study	suggest	that	SREBPs	may	have	direct	
or	indirect	regulation	of	proteins	outside	the	fatty	acid	pathways	and	may	regulate	cell	function	
at	multiple	levels.	This	study	also	shows	that	blocking	SREBP-1	activity	in	GBM	cells	promotes	
apoptosis	through	activation	of	the	caspase	cascade.		 
SCD-1	and	fatty	acid	synthase	are	primary	rate-limiting	enzymes	involved	in	the	biosynthesis	of	
long-chain	fatty	acids.		Both	SCD-1	and	fatty	acid	synthase	play	critical	roles	in	the	regulation	of	
carcinogenesis,	 cell	 proliferation	 and	 apoptosis26,27.	 Furthermore,	 inhibition	 of	 SREBP-1	
significantly	 down-regulated	 fatty	 acid	 synthase	 and	 SCD-1	 levels,	 indicating	 that	 SREBP-1	
inhibition	 regulates	 cancer-associated	 fatty	 acid	metabolism,	 thus	 inhibiting	 GBM	 cancer	 cell	
growth.	 Cancer	 cells	 including	 T98G	 cells	 have	 active	 signaling	 networks	 to	 meet	 their	 high	
demand	 for	 cholesterol28.	 Overexpression	 of	 HMGCoAR	 is	 involved	 in	 the	 global	 metabolic	
transformation	of	cancer	cells	and	high	levels	of	cholesterol	may	negatively	affect	the	outcome	
of	 chemotherapy29.	 	 It	 is	 also	 reported	 that	 blocking	 the	 intracellular	 supply	 of	 cholesterol	
through	inhibition	of	HMGCoAR	pathway	resulted	in	tumor	cell	death30.	Indeed,	in	our	study,	we	
demonstrate	that	inhibiting	SREBP-1	activity	with	PF429242	suppressed	expression	of	HMGCoAR.	
Fatty	acid	synthase,	SCD-1	and	HMGCoAR	are	three	primary	enzymes	at	rate-limiting	steps	for	
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biosynthesis	of	long-chain	fatty	acids	and	cholesterol.	Their	inhibition	significantly	limits	lipid	and	
cholesterol	 supply	 and	 thus,	 reduces	 the	 metabolic	 resources	 needed	 for	 uncontrolled	
proliferation	and	survival	of	GBM	cells.	Our	data	are	highly	suggestive	that	inhibiting	lipogenesis	
and	cholesterogenesis	are	key	to	reducing	cancer	cell	growth	and	may	offer	a	novel	mechanism	
in	developing	a	successful	therapy	for	GBM.	
It	is	important	to	monitor	and	ensure	that	these	chemotherapeutic	drugs	are	not	toxic	to	normal	
glial	cells	prior	to	in	Vivo	study.	In	the	rat	glia	data	showed	that	TMZ,	fatostatin,	PF429242	and	
Indip	inhibits	proliferation	of	normal	glial	cells	to	some	exstend	(Fig.	7).	The	IC50	values	of	TMZ	
are	comparable	to	what	is	shown	with	the	P98G	cells(talble	1	and	2),	we	assume	that	TMZ	will	
also	promote	healthy/normal		glial	cell	death	to	the	same	extent.	In	comparison,	Indip,	fatostatin	
and	Pf429242	are	less	cytotoxic	to	normal	glial	cells.		
In	conclusion,	our	current	study	showed	that	SREBP-1	regulates	FAS	and	SCD-1,	key	regulators	of	
fatty	 acid	 synthesis,	 as	well	 as	HMGCoAR,	 a	 key	 regulator	of	mevolonate	pathway	which	 are	
involved	in	the	global	metabolic	tumorigenicity	of	cancer	cells	including	GBM.	SREBP-1	has	been	
found	 to	 be	 up-regulated	 in	 GBM,	 making	 it	 a	 putative	 target.	 The	 data	 presented	 herein	
proposes	 a	 novel	 SREBP1-based	 paradigm	 in	GBM	 treatment.	We	 demonstrate	 that	 SREBP-1	
inhibition	regulates	the	expression	of	CDK-5	 in	T98G	cells	and	decrease	cancer	cell	migration.	
Additionally,	this	study	provides	evidence	for	the	clinical	significance	of	SREBP-1	inhibition	as	a	
novel	therapeutic	for	cancer.	Moreover,	these	studies	provide	proof-of-principle	evidence	that	
targeting	SREBP-1	and	its	regulatory	protein	Insig-1	may	provide	a	viable	therapeutic	approach	
for	 the	 treatment	 of	 GBM.	 Future	 studies	 should	 strive	 to	 investigate	 the	 impact	 of	 drug	
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combination	that	inhibit	multiple	regulators	of	SREBP-1	expression	and	activation	as	novel	cancer	
therapeutics.			
Table	1	
T98G	
CELL	
LINE	
Drugs		 Indip	 FATOSTATIN	 PF429242	 TMZ	
IC50	 of	
24hr(μM)	
250	 5	 10	 500	
IC50	of	48hr	
(μM)	
155	 2.64	 5.5	 334.3	
IC50	of	72hr	
(μM)	
192.4	 1.98	 3.9	 273.2	
	
Table	2	
Drugs		 Indip	 FATOSTATIN	 PF429242	 TMZ	
IC50	 of	
24hr(μM)	
320	 19.2	 23	 458.3	
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Rat	
Glial	
Cells	
IC50	of	48hr	
(μM)	
N/A	 17.4	 19	 438.4	
IC50	of	72hr	
(μM)	
N/A	 14	 12.5	 423.2	
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CHAPTER	3	
Sterol	regulatory	element-binding	protein	1	inhibitors	decrease	pancreatic	cancer	cell	viability	
and	proliferation	
	
ABSTRACT	
Sterol	regulatory	element-binding	protein1	(SREBP1)	is	a	key	regulatory	factor	that	controls	
lipid	homeostasis.	Overactivation	of	SREBP1	and	elevated	lipid	biogenesis	are	considered	the	
major	characteristics	in	malignancies	of	prostate	cancer,	endometrial	cancer,	and	glioblastoma.	
However,	the	impact	of	SREBP1	activation	in	the	progression	of	pancreatic	cancer	has	not	been	
explored.	The	present	study	examines	the	effect	of	suppression	of	SREBP1	activation	by	its	
inhibitors	like	fatostatin	and	PF429242	besides	analyzing	the	impact	of	inhibitory	effects	on	
SREBP1	downstream	signaling	cascade	such	as	fatty	acid	synthase	(FAS),	hydroxymethylglutaryl-
CoA	reductase	(HMGCoAR),	stearoyl-CoA	desaturase-1	(SCD-1),	and	tumor	suppressor	protein	
p53	in	MIA	PaCa-2	pancreatic	cancer	cells.	Both	fatostatin	and	PF429242	inhibited	the	growth	
of	MIA	PaCa-2	cells	in	a	time	and	concentration-dependent	manner	with	maximal	inhibition	
attained	at	72	h	time	period	with	IC50	values	of	14.5	μM	and	24.5	μM	respectively.	Detailed	
Western	blot	analysis	performed	using	fatostatin	and	PF429242	at	72	h	time	point	led	to	
significant	decrease	in	the	levels	of	the	active	form	of	SREBP1	and	its	downstream	signaling	
proteins	such	as	FAS,	SCD-1	and	HMGCoAR	and	the	mutant	form	of	tumor	suppressor	protein,	
p53,	levels	in	comparison	to	the	levels	observed	in	vehicle	treated	control	group	of	MIA	PaCa-2	
pancreatic	cells	over	the	same	time	period.	Our	in	vitro	data	suggest	that	SREBP1	may	
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contribute	to	pancreatic	tumor	growth	and	its	inhibitors	could	be	considered	as	a	potential	
target	in	the	management	of	pancreatic	cancer	cell	proliferation.	
	
INTRODUCTION		
Pancreatic	cancer	is	the	4th	leading	cause	of	cancer-related	death	in	the	USA,	with	only	a	6%	
survival	rate	in	5	years	[1].	The	low	survival	rate	is	due	to	early	recurrence	and	metastasis	of	
pancreatic	carcinoma,	and	also	the	late	stage	diagnosis	due	to	its	asymptomatic	nature	[2].	
Over	the	past	few	years,	several	targets	such	as	the	epidermal	growth	factor	receptor	(EGFR),	
Phosphatidylinositol	3-kinase	(PI3K),	protein	kinase	B	(Akt)	the	mechanistic	target	of	rapamycin	
(mTOR)	and	B-Raf	have	been	developed	and	tried	for	the	inhibition	of	different	cancers.	
Currently,	the	EGFR	inhibitor,	erlotinib,	in	combination	with	gemcitabine	has	been	approved	for	
the	treatment	of	pancreatic	cancer	[3].	While	inhibiting	these	upstream	targets	has	been	
successful	for	treating	several	types	of	cancers,	these	therapies	are	either	ineffective	or	lead	to	
a	development	of	resistance	over	time.	Knowing	the	complex	tumor	biology	of	pancreatic	
cancer,	identification	of	new	targets	and	therapies	is	an	urgent	unmet	medical	need.	
It	is	now	a	well-established	fact	that	tumor	cells	readjust	their	metabolic	pathways	to	meet	the	
need	of	cancer	cells	[4].	In	malignant	cells,	mainly	lipid	metabolism	gets	reprogrammed	to	meet	
high	metabolic	demands	of	cancer	cells	and	the	lipogenic	phenotype	is	a	significant	
characteristic	of	tumors.	Tumor	cells	also	divert	glucose	and	glutamate	metabolism	pathways	to	
serve	in	lipid	biogenesis	process	[5].	Sterol	regulatory	element-binding	proteins	(SREBPs)	are	
key	transcription	factors	that	control	lipid	homeostasis	[6].	There	are	two	types	of	SREBPs,	
SREBP1,	which	mainly	regulates	fatty	acid	synthesis,	and	SREBP2,	which	activates	cholesterol	
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synthesis	[7].	The	elevated	lipid	biogenesis	regulated	by	SREBP1	is	considered	a	major	
characteristic	of	malignancies	including	prostate	cancer,	endometrial	cancer,	and	
glioblastoma	[8]	;		[9].	SREBP1	acts	as	a	central	regulator	in	integrating	glucose	metabolism	
regulated	by	PI3K/Akt	signaling	pathway	and	fatty	acid	synthesis	by	Myc-regulated	glutamine	
metabolism	[10].	The	active	N-terminal	region	of	SREBP1	localized	in	the	nuclei	upregulates	
expression	of	several	downstream	target	genes	such	as	fatty	acid	synthase	(FAS)	and	steaoryl-
CoA-desaturase-1	(SCD-1)	[11].	The	oncogenic	receptor	tyrosine	kinase	(RTK)/PI3K/Akt	pathway	
increases	the	expression	of	SREBP-1	which	in	turn	upregulates	ATP	citrate	lyase	(ACL),	Acetyl-
CoA	carboxylase	(ACC)	and	fatty	acid	synthase	(FAS)	to	promote	fatty	acid	synthesis	and	
increase	low	density	lipoprotein	receptor	expression	to	increase	cholesterol	uptake	by	these	
malignant	cells.	The	fatty	acids	and	phospholipids	promote	cell	growth	and	survival.	A	recent	
study	also	showed	that	inhibition	of	upstream	events	such	as	EGFR,	PI3K,	and	Akt	activation	
lead	to	drastic	reduction	in	the	expression	of	SREBP1	in	cancer	cells	[11].	While	a	clear	positive	
correlation	between	SREBP-1	level	and	pancreatic	cancer	cell	proliferation	has	been	
addressed	[6],	whether	the	inhibitors	of	SREBP1	would	affect	pancreatic	cell	has	not	been	
explored	so	far.	
Therefore,	we	analyzed	the	effect	of	two	known	inhibitors	of	SREBP1,	fatostatin	and	PF429242,	
on	a	human	pancreatic	cancer	cell	line,	MIA	PaCa-2	cells.	Fatostatin	is	a	non-sterol	synthetic	
diarylthiazole	derivative	which	inhibits	SREBP1	maturation	and	its	nuclear	translocation	[12].	
PF429242	is	a	reversible,	competitive	aminopyrrolidineamide	inhibitor	of	site-1	protease	(S1P),	
which	inhibits	endogenous	SREBP	processing	[13].	We	investigated	the	effect	of	these	two	
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inhibitors	on	pancreatic	MIA	PaCa-2	cells'	viability	as	well	as	their	effects	on	SREBP1	activation	
and	its	key	downstream	targets.	
	
RESULTS	
3.1.1	Fatostatin	and	PF429242	both	display	concentration	and	time-dependent	further	
increases	in	their	inhibitory	effects	in	the	MIA	PaCa-2	cell	line	
First,	we	determined	the	cytotoxic	effect	of	fatostatin	and	PF429242	in	the	MIA	PaCa-2	cell	line	
as	a	function	of	time	by	incubating	them	for	varying	time	intervals	of	24,	48	and	72	h	at	
concentration	ranges	(10–320	μM)	employing	the	CCK-8	assay.	While	significant	inhibition	
(P	<	0.001)	was	observed	even	at	24	h	period	of	incubation	using	either	agent	at	their	lowest	
concentration	(10	μM)	employed	in	the	study	(	Fig.	1A	and	B	upper	panel)	both	agents	display	
concentration	and	time-dependent	further	increases	in	their	inhibitory	effects	(Fig.	1A–F).	The	
IC50	values	were	found	to	be	14.5	μM	and	24.5	μM	for	fatostatin	and	PF429242,	respectively	at	
72	h	time	of	incubation.	
3.1.2			Western	blot	analysis	showed	a	significant	decrease	in	active	form	of	SREBP-1	and	its	
downstream	signaling	proteins	FAS	and	HMGCoAR		
Western	blot	analysis	showed	a	significant	decrease	in	active	form	of	SREBP1	(P	<	0.001)	and	its	
downstream	signaling	proteins	FAS	(P	<	0.001),	SCD-1	(P	<	0.001)	and	HMGCoAR	(P	<	0.001)	in	
MIA	PaCa-2	cells	when	compared	to	the	levels	of	these	protein	seen	in	normal	mice	pancreatic	
tissue	homogenates	(N).	Treatment	with	both	fatostatin	(IC50	14.5	μM	for	72	h)	and	PF429242	
(IC50	24.5	μM	for	72	h)	significantly	decreased	the	levels	of	active	form	of	SREBP-1	(P	<	0.05	
and	P	<	0.01,	respectively;Fig.	2B),	FAS	(P	<	0.05	and	P	<	0.05,	respectively;	Fig.	2C),	SCD-1	
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(P	<	0.01	and	P	<	0.001,	respectively;	Fig.	2D),	HMGCoAR	(P	<	0.01	for	PF429242;	Fig.	2E)	and	
p53	(P	<	0.05	and	P	<	0.001,	respectively;	Fig.	2F)	in	MIA	PaCa-2	cells	in	comparison	to	vehicle	
treated	control	group	of	MIA	PaCa-2	cells	maintained	over	the	same	time	period.	
3.2.1	FIGURE	1	
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FIGURE	LEGEND	1	
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Effects	of	inhibition	of	MIA	PaCa-2	pancreatic	cancer	cell	proliferation	in	vitro	attained	with	
increasing	concentrations	of	either	fatostatin	(10–320	μM)	or	PF429242	(10–320	μM)	for	24	h	
(upper	panel	Fig.	1A	and	Fig.	1B),	48	h	(middle	panel	Fig.	1C	and	Fig.	1D)	and	72	h	(lower	panel	
Fig.	1E	and	Fig.	1F)	periods	of	incubation.	Each	bar	diagram	represents	mean	±	standard	
deviation	(S.D.)	of	mean	values	of	%	of	viable	cells	(n	=	3	separate	experiments	performed	in	
triplicate).	***P	<	0.001	compared	to	respective	vehicle-treated	control	group	(C)	of	MIA	PaCa-
2	pancreatic	cells.	
	
	
	
	
	
	
	
	
	
	
3.2.2	FIGURE	2	
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FIGURE	LEGEND	2	
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Western	blot	data	for	the	effects	of	fatostatin	and	PF429242	on	MIA	PaCa-2	pancreatic	cancer	
cell	line.	The	representative	Western	blots	for	the	levels	of	active	SREBP-1,	fatty	acid	synthase	
(FAS),	stearoyl-CoA-reductase-1	(SCD-1),	HMGCoAR,	tumor	suppressor	protein,	p53,	along	with	
b-actin	determined	in	normal	mouse	pancreatic	tissue	homogenate	(N),	in	vehicle-treated	
control	group	(C),	fatostatin	(FAT	IC50	-	42.5	mM	for	48	h)	and	PF429242	(PF	IC50	47	mM	for	48	
h)	treated	MIA	PaCa-2	pancreatic	cells	are	shown	(Fig.	2A).	The	Western	blot	data	analyzed	
from	several	experiments	are	presented	as	bar	diagrams	[mean	±	S.D.	values,	n	=	3)	for	the	
levels	of	active	SREBP-1	(Fig.	2B),	FAS	(Fig.	2C),	SCD-1	(Fig.	2D),	HMGCoAR	(Fig.	2E),	p53	(Fig.	2F)	
determined	seen	in	normal	mouse	pancreatic	tissue	homogenate	(N)	vs.	the	control	group	of	
vehicle	treated	group	(C)	or	fatostatin	(FAT)	or	PF429242	(PF)	treated	MIA	PaCa-2	pancreatic	
cells	maintained	in	vitro	in	culture.	T¸	denotes	P	<	0.001	in	normal	mouse	pancreatic	tissue	
homogenate	(N)	compared	to	the	levels	noted	in	vehicle	treated	control	group	MIA	PaCa-2	
pancreatic	cancer	cells	(C).	*P	<	0.05,	**P	<	0.01,	***P	<	0.001	in	FAT	or	PF	treated	cells	
compared	to	respective	vehicletreated	control	group	(C)	of	MIA	PaCa-2	cells.	
MATERIALS	AND	METHODS		
3.3				materials	
MIA	PaCa-2	cell	line	was	obtained	from	Sigma-Aldrich	(Sigma-85062806).	Dulbecco's	Modified	
Eagle	Medium	(Hyclone	DMEM),	fetal	bovine	serum	(FBS)	were	purchased	from	HyClone	(Cat	
No:	SH30024.01).	Cell	Counting-8	(CCK-8)	kit	was	purchased	from	Dojindo	(Cat	No:	LT807).	
Fatostatin	was	obtained	from	TOCRIS	BIOSCIENCE	(Catalog	No:4444).	PF429242	was	obtained	
from	SIGMA	(Catalog	No:	SML0667).	
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3.3.1	Maintenance	of	tumor	cell	line	
MIA	PaCa-2	cell	line	was	authenticated	by	Sigma-Aldrich,	Canada	(Invoice	No.	536284272;	
dated	06/22/2015).	These	cells	were	grown	in	Hyclone	DMEM	with	10%	FBS	and	cultured	in	a	
humidified	atmosphere	of	5%	CO2	at	37	°C.	
3.3.2	Cytotoxicity	assay	
MIA	PaCa-2	cells	(4000	cells/well)	were	seeded	in	96-well	plates	with	the	medium	mentioned	
above.	After	overnight	attachment,	the	cells	were	treated	with	the	medium	containing	either	
fatostatin	(0–320	μM)	or	PF429242	(0–320	μM)	for	24,	48	and	72	h	(6	wells/concentration).	
Fatostatin	(1	mM)	was	initially	dissolved	in	dimethyl	sulfoxide	while	PF429242	was	dissolved	in	
sterile	water	and	further	dilutions	of	each	inhibitors	were	made	in	Dulbecco's	modified	
essential	medium.	The	viable	cell	number	was	measured	using	the	CCK-8	assay	kit.	Absorbance	
was	measured	at	450	nm	using	a	microplate	reader	(Spectral	Max	M5).	The	optical	density	of	
each	well	was	measured	to	represent	the	proliferation	of	the	cells.	All	the	experiments	were	
performed	in	triplicate.	
3.3.3	Western	blot	analysis	
MIA	PaCa-2	cells	were	plated	in	10	cm	Petri	dishes.	After	overnight	attachment,	the	cells	were	
treated	with	either	vehicle	(control),	PF429242	or	fatostatin	for	72	h.	The	concentrations	of	
fatostatin	and	PF429242	employed	were	chosen	based	on	the	IC50	values	derived	from	
preliminary	studies.	For	total	protein	extraction,	cells	were	lysed	in	RIPA	buffer	(Cell	Signalling,	
#9806,	20	mM	Tris-HCl	pH	7.5,	150	mM	NaCl,	1	mM	Na2EDTA,	1	mM	EGTA,	1%	NP-40,	1%	
sodium	deoxycholate,	2.5	mM	sodium	pyrophosphate,	1	mM	β-glycerophosphate,	1	mM	
Na3VO4,	1	μg/ml	leupeptin)	supplemented	with	protease	inhibitor	cocktail	(Cell	Signaling,	
70		
#5871).	Normal	pancreatic	tissues	were	obtained	from	2	months	old	male	and	female	C57BL/6	
mice.	The	mice	were	euthanized	by	cervical	dislocation	under	mild	anesthesia	(isoflurane),	the	
pancreas	was	excised	out	and	processed	for	whole	cell	lysates	similar	to	the	Mia	PaCa-2	cell	
lysates	as	mentioned	above.	Total	protein	extracts	were	quantified	using	the	Bradford	assay	
with	bovine	serum	albumin	as	standard.	Western	blot	experiments	were	carried	out	using	the	
Mini	Trans-Blot	cell	BIO-RAD.	The	following	primary	antibodies	were	used:	anti-FAS	(Santa	Cruz,	
sc-48357;	dilution	1:500),	anti-SCD1	(Abcam,	ab19862;	dilution	1:1000),	anti-	HMGCoAR	
(Abcam,	ab174830;	dilution	1:1000),	anti-SREBP1	(Santa	Cruz,	sc-365513,	1;	500)	and	anti-p53	
(Abcam,	ab1101;	dilution	1:1000).	Anti-beta	Actin	(Abcam,ab8227;	dilution	1:1000)	was	used	
for	normalization.	All	the	experiments	were	performed	in	triplicate.	
3.3.4	Statistical	analysis	
All	the	statistical	analyses	were	conducted	using	Graphpad	Prism		6	software	(GraphPad	
Software,	San	Diego,	CA).	Data	are	presented	as	mean	±	standard	deviation	(SD).	For	western	
blots,	the	protein	expressions	for	various	conditions	were	compared	by	one-way	ANOVA	
test.	P	values	<	0.05	were	considered	as	statistically	significant.	
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DISCUSSION	
There	is	increasing	evidence	that	cancer	cells	engage	in	increased	lipogenesis	to	become	
independent	of	systemic	regulation,	leading	to	rapid	cell	proliferation	and	enhanced	tumor	
growth	[7]	;		[10].	Therefore,	recent	studies	have	explored	the	role	of	SREBP1	as	a	novel	
molecular	target	in	several	cancers.	The	data	from	the	present	study	shows	that	SREBP1	and	its	
downstream	signaling	protein	were	increased	in	pancreatic	cancer	cells	and	the	inhibition	of	
SREBP1	overactivation	using	either	fatostatin	or	PF429242	led	to	a	significant	reduction	in	the	
downstream	signaling	proteins	with	both	agents	displaying	a	similar	degree	of	time	and	
concentration-dependent	inhibition	of	MIA	PaCa-2	pancreatic	cell	proliferation.	
Precursor	SREBP1	is	bound	to	the	ER	membranes,	which	upon	activation	undergoes	two-step	
cleavage	and	releases	the	N-terminal	active	form	of	SREBP1	in	the	nucleus.	Fatostatin	decreases	
the	amounts	of	fatty	acid,	triglyceride	and	low-density	lipoprotein	by	disturbing	the	activation	
of	SREBP1	[12].	PF429242	a	reversible,	competitive	inhibitor	of	endogenous	processing	of	
SREBP1	decreases	lipid	biosynthesis	[13].	
SREBP	genes	also	regulate	expression	of	HMGCoAR,	a	rate-limiting	enzyme	of	the	mevalonate	
pathway	[14].	HMGCoAR	is	a	common	target	of	statins	used	to	treat	high	levels	of	cholesterol.	
Statins	have	been	shown	to	exert	anticancer	activity	in	vitro	and	in	preclinical	models	[15].	
However,	clinically,	it	was	confirmed	that	statins	did	not	have	any	impact	on	reducing	cancer	
burden	[16]	;		[17].	An	increase	in	SREBP1	induces	the	expression	of	several	enzymes	involved	in	
lipid	synthesis	such	as	FAS,	HMGCoAR,	and	SCD-1.	We	observed	that	inhibition	of	SREBP1	led	to	
decreased	expression	of	these	enzymes	in	the	pancreatic	cancer	cell	line.	
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p53,	a	tumor	suppressor	oncogene,	is	mutated	in	more	than	75%	of	cancer	cases	[18].	The	
presence	of	a	mutant	form	of	p53	is	always	detected	in	rapidly	growing	pancreatic	cancer	
cases	[19].	The	Hippo	signaling	and	p53	pathways	influence	the	expression	of	SREBP	mRNA	and	
SREBP	transcriptional	activity	[14].	Wild-Type	p53	represses	transcription	of	SREBP1	[20].	p53	
deletion	has	been	shown	to	increase	the	expression	of	SREBP1	and	its	downstream	targets	
(including	FAS)	in	mice	[20].	In	the	case	of	mutant	p53,	gain-of-function	mutants	p53R273H	and	
p53R280K	bind	with	SREBPs	and	activate	their	transcriptional	activity.	As	shown	in	Fig.	2,	MIA	
PaCa-2	cells	show	high	expression	of	p53	and	perhaps	mutated	p53	[12].	Both	fatostatin	and	
PF429242	significantly	reduced	the	expression	of	p53.	We	also	observed	two	sterol	regulatory	
element	sequences	(5ʹ-ATCACCCCAC-3ʹ)	with	100%	homogeneity	in	p53	gene	sequence	at	
1904–1911	and	2350–2358	base	pairs	in	BLAST	analysis	suggesting	a	potential	regulatory	role	of	
SREBP1	over	p53	gene	expression.	Thus,	we	speculate	that	since	the	majority	of	p53	is	mutated	
in	tumor	cells,	the	reduction	in	the	level	with	SREBP1	inhibitors	most	likely	reflects	a	reduction	
in	the	mutant	form	of	p53.	Li	et	al.	have	also	noted	that	fatostatin	has	antitumor	effects	in	
mutant	p53	metastatic	prostate	cancer	cells	[12].	It	is	noteworthy	that	in	our	present	study	we	
have	supportive	data	that	the	normal	pancreatic	tissues	obtained	from	mice	expressed	a	very	
low	level	of	SREBP1	as	well	as	the	downstream	targets	FAS,	HMGCoAR	and	SCD-1.	This	clearly	
shows	that	SREBP1	and	its	downstream	targets	are	overexpressed	and	activated	in	cancer	cells	
as	a	result	of	the	changes	in	the	lipid	metabolism	pathways	described	in	the	earlier	sections.	
In	summary,	the	data	from	the	present	study	using	two	selective	inhibitors	of	SREBP1	confirm	
that	both	agents	exert	selective	cytotoxicity	in	MIA	PaCa-2	pancreatic	cancer	cells	along	
reduction	of	proteins	involved	in	lipid	biosynthesis.	These	data	suggest	SREBP1	inhibition	could	
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serve	as	a	potential	target	to	explore	in	combination	with	the	first	line	chemotherapy	to	
improve	prognosis	in	pancreatic	cancers.	
Future	Directions		
GBM	is	one	of	the	deadliest	malignancies,	with	a	very	short	life	expectancy	after	it	is	diagnosed.	
Unfortunately,	there	is	no	effective	treatment	for	GBM	as	average	survival	after	surgery,	
chemotherapy,	and	radiotherapy	is	estimated	to	be	about	14-15	months.	Recent	extensive	
media	coverage	on	GBM,	following	diagnosis	of	celebrities	and	politicians	such	as	famous	singer	
Gordon	Downie	and	Senator	John	McCain	with	malignant	brain	tumors	has	drawn	a	great	deal	
of	attention	to	this	disease	and	accelerated	efforts	in	drug	discovery.	To	pursue	my	current	
research,	I	propose	and	envision	the	following	potential	research	avenues	and	goals:			
1. To	study	effects	of	SREBP1	inhibitors	on	patient	GBM	tumor	stem	cells.	One	of	the	
major	reasons	for	conventional	chemotherapy	failure	in	cancers,	including	GBM	tumors,	
is	the	propagation	and	proliferation	of	unresponsive	tumor	stem	cells.	We	are	planning	
to	gain	access	to	small	sections	of	GBM	tumors	resected	from	patients	and	expose	
isolated	stem	cells	to	various	SREBP1	inhibitors	alone	and	in	combination	with	each	
other	or	with	conventional	chemotherapeutic	agents	such	as	TMZ.	
2. Using	immune	system	compromised	xenograft	mice	is	considered	the	next	transitional	
step	from	in	vitro	study	to	in	vivo	model.	I	will	screen	and	evaluate	the	effectiveness	of	
SREBP1	inhibitors	(alone	or	in	combination)	in	a	NoD-SCID	xenograft	mouse	model.	
3. As	an	ongoing	SHRF	CID	collaboration	between	my	supervisor	and	Dr.	Maruti	Uppalapati	
(Department	of	Pathology,	University	of	Saskatchewan),	they	are	investigating	short	
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peptide	domains	as	novel	SREBP1	inhibitors.	I	can	screen	any	peptide	fragments	
generated	from	this	collaboration	against	GBM	using	in	vitro	and	in	vivo	models.	
4. 		Although	Indip	peptide	crosses	the	BBB	because	of	TAT	fusion,	using	Indip	and	other	
SREBP1	inhibitors	as	well	as	TMZ	loaded	nanoparticles	to	improve	drug	delivery	into	the	
CNS	can	also	be	considered	a	feasible	study	for	the	continuation	of	this	project.	
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